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ABSTRACT OF DISSERTATION

ROLE OF ALTERNATIVE MACROPHAGE ACTIVATION IN MEDIATING FIBROSIS IN
PSEUDOMONAS AERUGINOSA PNEUMONIA
Patients with cystic fibrosis who are infected with the pathogen Pseudomonas
aeruginosa have shown favorable responses to the drug azithromycin (AZM). This drug
works in an anti-inflammatory capacity, improving clinical outcomes and improving
quality of life in this population. The drug has also been shown to affect macrophage
polarization by shifting these cells away from an inflammatory phenotype toward an
alternatively activated anti-inflammatory phenotype. The full impact of this phenotypic
change is not well understood in the context of the response to P. aeruginosa infection,
or the overall immune response in cystic fibrosis.
To understand how the AZM-polarized macrophage affects other types of cells,
we utilized a co-culture in vitro system, with macrophages and fibroblasts incubating
together. In this system, we determined that AZM causes upregulation of the pro-fibrotic
mediator transforming growth factor-β as well as the extracellular matrix (ECM) protein
fibronectin. The mediator of ECM turnover, matrix metalloproteinase (MMP)-9 was
upregulated in this system as well. In an in vivo model of P. aeruginosa infection, MMP9 and fibronectin were increased in the bronchoalveolar lavage 7 days post-infection in
mice that were treated with AZM. This was accompanied by a decrease in damage to
the lung tissue, determine by histological examination. To determine if these changes
would continue in human subjects with cystic fibrosis, a clinical study was done in this
population. Subjects with AZM treatment had decreased TGF-β levels, but no
differences in MMP-9 or fibronectin. Interestingly, correlations between certain fibrotic
mediators and inflammatory cytokines, specifically interleukin -1β, were different in
subjects with AZM treatment compared to subjects without AZM therapy. Together,
these data indicate that AZM alters the fibrotic response from the macrophages, as well
as the interaction of the inflammatory response and fibrosis development.
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Chapter 1: Introduction
A. Pulmonary Infection in Cystic Fibrosis
Overview
Cystic fibrosis (CF) is a genetic disorder affecting 30,000 people in the United
States. The mutation in the Cystic Fibrosis Transmembrane Regulator gene (CFTR)
causes a defect in the chloride transporter that it encodes. Over 1,000 mutations in the
CFTR gene have been identified. This defect results in reduced movement of chloride
ions, subsequently altering sodium transport and water movement, changing the airway
surface liquid (ASL) depth.[1] The mutation affects multiple organs, but the impact is
most prominent in the lungs, most likely due to the changes in ASL and the associated
consequences. The most common mutation, ΔF508, results in a missense mutation
which causes a defect in processing, rendering the protein unable to reach the cell
membrane. [2] Other missense mutations, such as G551D, result in a protein at the cell
membrane that is improperly regulated, and therefore non-functional. The variation in
mutations that lead to disease result in a variety of disease phenotypes, ranging from
mild to severe disease.[3] Those mutations which cause mild pulmonary disease may
leave other organs unaffected. The more severe mutations cause other clinical
manifestations, including pancreatic insufficiency.[4] Cystic fibrosis pathology is
characterized by increased mucus secretions in the pulmonary spaces, which provide an
excellent environment for frequent bacterial infection.[5] Patients with CF are colonized
with a wide variety of bacteria. Infections early in the progression of the disease are
commonly caused by pathogens that also commonly cause disease in non-CF children
and adults, such as methicillin-sensitive Staphylcoccus aureus and Haemophilus
influenzae.[6] However, by their teen years and into adulthood, most patients become
infected with more serious pathogens that produce damaging virulence factors and
1

multiple resistance mechanisms, such as methicillin-resistant S. aureus (MRSA), P.
aeruginosa, and Burkholderia cepacia complex.[5] These organisms are not commonly
observed to cause infection in the normal, immunocompetent population. They produce
exacerbations that are extremely damaging to lung function and quality of life in this
patient population. Especially in the case of P. aeruginosa (and more recently MRSA)
patients with CF have extreme difficulty clearing these pathogens, resulting in chronic
colonization.[7, 8] In fact, according to the most recent epidemiological data from the
Cystic Fibrosis Registry, a national database that tracks infection incidence, up to 80%
of patients in their late teens to early twenties typically become chronically infected with
Pseudomonas aeruginosa.[9] As approximately 85% of CF mortality is due to
pulmonary complications, this is an important focus for research efforts.
The mutation in the CFTR gene is the direct cause of the increased mucus
secretions in the lung. As stated above, the damage to the pulmonary system can
cause significant morbidity and mortality to the CF population. Damage to the lungs
during the course of disease occurs in a cyclical fashion (Figure 1.1); mucus buildup
provides an ideal environment for bacterial infection, which results in a hyperinflammatory response from the CF immune system. This response, in clearing the
bacterial infection, causes damage to the patient’s pulmonary tissue as a result.
Neutrophils, the major infiltrating cell type, release a multitude of peptidases and
elastases, causing damage to the alveolar interstitium.[10] As the inflammation begins
to resolve, if damage is severe enough, the repair processes orchestrate remodeling that
results in scarring, causing an even greater difficulty in clearance of mucus, which leads
to more bacterial infections.[11] By the time the patient is nearing adulthood, they are
subject to chronic infections, a buildup of fibrosis and scarring in their lungs, and a
quantity of mucus that is difficult to dissipate. This cumulative damage ultimately results
in pulmonary function decline, which is measured with pulmonary function tests. Forced
2

expiratory volume in one second (FEV1), tracks the compliance of the lung, and is used
as a clinical measurement of lung function, and corresponding disease severity. As
FEV1 declines, patients are less able to move air through their lungs, resulting in severe
morbidity and ultimately death of the patient. [12]

Figure 1.1. Cystic fibrosis pulmonary disease progresses in a cyclical fashion.

Inflammatory Response
In addition to the increased susceptibility to bacterial infection, patients exhibit
vigorous inflammation early in their disease; the inflammatory response causes
widespread tissue damage in addition to killing the bacteria. It has been shown that the
CFTR is directly linked to this hyperinflammation; lack of the CFTR has been shown to
cause upregulation of nuclear factor (NF)-κB and toll-like receptor (TLR)-4 mistrafficking,
both of which lead to an increase in inflammatory cytokine expression.[11, 13, 14] The
bacterial cell wall component lipopolysaccharide (LPS) binds to the TLR-4 receptor,
triggering downstream signaling that ultimately activates NF-κB. In macrophages that
have the CFTR mutation, TLR-4 degradation is inhibited, resulting in prolonged
activation of downstream molecules, including NF-κB.[14] In addition, deregulated
3

signaling from interleukin (IL)-1β and tumor necrosis factor (TNF) receptors also prolong
NF-κB activation.[13] This mistrafficking is demonstrated in macrophages and epithelial
cells; the result is that they produce cytokines and chemokines which recruit more
inflammatory cells to the airways.[15-17] The cellular infiltrates are predominately
neutrophils, which release proteases, such as matrix metalloprotease(MMP)-9 and
neutrophil elastase (NE).[18] While these proteases are vital for bacterial clearance, in
the CF airway the burden of protease overcomes the presence of naturally produced
anti-proteases, shifting the effects toward airway damage and ultimately
bronchiectasis.[19] In fact, neutrophils and their associated cytokines are increased in
BAL from patients with CF when infection cannot be detected.[20] Because of the
continued NF-kB signaling, constant influx of neutrophils and release of proteases, the
inflammation characteristic of the disease is more of a prolonged acute response rather
than chronic inflammation.[21]
While neutrophils are the primary mediating cell type, T cells are also involved in
the exaggerated inflammatory response in patients with CF. Infection leads to a subset
of CD4+ T cell response known as Th1, which involves inflammatory cytokines such as
IL-1β, IL-6, IFN-γ, and TNF.[22] This response is characteristic of these patients early in
the course of their disease (Figure 1.2). The highly inflammatory response, while
vigorous, is necessary for clearance of the bacteria. Furthermore, a Th1 response has
been associated with better outcomes in P. aeruginosa infection, as opposed to a Th2predominant response.[23] However, as disease progresses, patients’ immune
responses tend to switch to a subset of T cell response known as Th2-mediated
polarization.[24, 25] Despite being associated with repair instead of inflammation, a Th2
response is associated with worse outcomes for P. aeruginosa infection[23]. In contrast
to a Th1 response, Th2 responses are induced by the cytokines IL-4 and IL-13 (Figure
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1.2). T cell response is of primary interest here because the cytokines produced by T
cells can influence cells of the innate immune response, including macrophages.
Macrophages can respond to cytokines produced by T cells, and can affect the
adaptive immune system in return. Because they are an important part of the innate
immune response, these cells respond initially to pathogens, but are also present
throughout the infection. In response to the cytokines produced by Th1 and Th2 type T
cells, macrophages are polarized to two distinct phenotypes; classically activated
macrophages (CAM) or alternatively activated macrophages (AAM), respectively. [26]
IFN-γ, produced by the Th1 response, polarizes macrophages to the CAM
phenotype, especially when combined with a pathogen trigger such as
lipopolysaccharide (LPS), as shown in Figure 1.3.[27] The primary effector protein of the
CAM is inducible nitric oxide synthase (iNOS), which metabolizes L-arginine to produce
nitric oxide (NO). Along with oxygen radicals, NO is one of the major bactericidal
components of the lysosomes in the CAM, and mainly responsible for its efficiency at
bacterial killing.[28] Furthermore, the signaling cascades induced by IFN-γ and LPS
stimulate the NF-κB pathway, upregulating the production of inflammatory cytokines.
Therefore, this macrophage phenotype is associated with inflammation, bacterial
clearance, and damage.[29]
The macrophages that are alternatively activated can be stimulated by a variety
of triggers; IL-4 and IL-13, TGF-β, IL-10, and glucocorticoids, each one resulting in a
different phenotype and different gene expression patterns.[30] Some of these AAM
subsets are summarized in Table 1.1. As noted in the table, some of the triggers and
products can overlap between the subsets, making characterization of the specific
macrophage phenotype complex. Here, the subset induced by IL-4 and IL-13 will be the
primary focus. Macrophages stimulated by IL-4/13 downregulate iNOS and increase
production of the effector protein arginase in its place, as shown in Figure 1.3.[26] The
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enzyme metabolizes the same substrate, L-arginine, to produce L-ornithine.[31] Without
products such as NO, the macrophages are less efficient at killing bacteria, and become
involved in clearing away cellular debris.[32, 33] Further, the products from arginase are
further converted to prolines and polyamines, which are precursors to collagen
production.[29] In this way, AAM are associated with an increase in collagen deposition
and therefore participate in mechanisms of tissue repair, as discussed below. While T
cells are terminally differentiated into Th1 or Th2 subtypes, macrophages retain plasticity
and can be polarized into another phenotype. Because alveolar macrophages can
influence the immune environment and response to bacterial infection in the pulmonary
spaces, AAM are a target of investigation in multiple infection models, including those
caused by fungal pathogens and respiratory syncytial virus.[34] This dissertation will
examine, in part, the role of the AAM response to infection with Pseudomonas
aeruginosa.

Figure 1.2. Response of T cell subsets in CF disease progression.

6

Figure 1.3. Polarization subtypes of macrophages.

Table 1.1. Function and markers of different macrophage phenotypes. Listed are the
macrophage phenotype, the stimulation necessary to polarize an inactive macrophage to
that phenotype, the function of the cell, surface markers, functional markers, and the
cytokines produced (adapted from [27, 35, 36].

B. Alternatively Activated Macrophages and Fibrosis
Alternatively activated macrophages, the phenotype of macrophage induced by
IL-4 and IL-13, produced primarily by Th-2 polarized T cells, have very distinct effector
proteins produced. Typically they are identified by increased arginase activity and
upregulated mannose receptor expression. The AAM subtype is also marked by higher
7

rates of antigen endocytosis, the expression molecule found in inflammatory zone 1
(FIZZ-1) and the molecule Ym1.[27, 37, 38] Other markers include increased
expression of IL-10, CD23, and chemokine (C-C motif) ligand (CCL)-18.[32] Paired with
these changes are downregulation of inflammatory mediators and enzymes, such as
iNOS, CD80, and the chemokine receptor CCR7, that are CAM markers.
Without iNOS, which produces NO and other oxygen radicals that are the
molecules that allow classically activated macrophages to be efficient bacterial killers,
AAMs are more effective at clearing debris than killing pathogens.[39] Along with the
decrease in inflammatory and bactericidal effects are an association of AAMs with
increased mediators of extracellular matrix (ECM) production through the upregulation of
arginase, a fibrotic precursor.[40] Arginase catalyzes the conversion of L-arginine to
urea and L-ornithine; L-ornithine is a precursor to prolines and polyamines, which are
then used to make collagens and other fibrogenic proteins that make up the ECM.[27]
[41]
In fact, alveolar macrophages isolated from patients with several types of
pulmonary fibrotic diseases display characteristics of alternative activation. These cells
also cause normal lung fibroblasts to increase collagen production when the two cells
types are incubated ex vivo. [40] This effect on fibroblasts appears to be through the
macrophage production of chemokine CCL-18, which is increased in AAM and can
recruit naïve T cells.[32] Gene expression of CCL-18 was increased after Th2 cytokine
exposure, suggesting this chemokine may be part of a positive feedback loop of fibrosis
perpetuation by fibroblasts. In this study by Prasse et al, the effect on fibrosis increase
occurred with incubation of Th2 cytokines and presence of an infectious agent was not
necessary.[40]
Th2 cytokines are also associated with fibrosis as demonstrated in a murine
model of pulmonary fibrosis using a strain of transgenic mouse which over expresses IL8

13. In this study, fibrosis was increased directly through increased activation of
transforming growth factor (TGF) –β, a chemokine with both anti-inflammatory and profibrotic properties. [42] Here, the development of fibrosis was dependent solely on the
overexpression of IL-13 in the absence of infection, and was blocked through the
administration of a TGF-β antagonist. Here, TGF-β was localized to macrophages by
histology, showing that macrophages do upregulate this fibrotic mediator after exposure
to IL-13, a primary Th2 cytokine.
Likewise, arginase and TGF-β have been associated with fibrogenesis in multiple
models of lung injury and repair. This suggests that the alternatively polarized
macrophages are major mediators of pulmonary fibrogenesis. Genetically engineered
hTGF-β-1 transgenic mice, which overexpress human bioactive TGF-β, were treated
with doxycycline to induce a pulmonary fibrosis phenotype, displayed increased arginase
produced by mononuclear cells, identified by the common macrophage marker F4/80.
[43] These mononuclear cells producing arginase were isolated from bronchoalveolar
lavage fluid, showing that they were alveolar macrophages participating in the
pulmonary fibrosis response. Likewise, in a model of murine allergic asthma,
subepithelial fibrosis was shown to be reduced by the small molecule mepacrine.[44]
Administration resulted in reduced arginase and TGF-β expression in the allergic asthma
model, likely secondary to the reduced levels of IL-4 and IL-13 also seen with mepacrine
treatment. Also, pirfenidone, a drug under investigation for IPF, has been shown to
inhibit both arginase and TGF-β, though the mechanism is unclear. [45]
Combined, this evidence shows that the prolonged presence of AAM could be
detrimental to the pulmonary environment and participate in the upregulation of fibrotic
mediators. However, it is important to note that macrophage polarization is not terminal,
and once polarized to one phenotype, the cell can be polarized to another phenotype
when the cytokines present are altered. When Th1 cytokines are added to AAM cells,
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those cells lose their alternative markers and take on classical characteristics.[46] It is
also important to remember that, while the AAM can be pro-fibrotic, their antiinflammatory properties may make them more protective than harmful long-term.[27]

C. Transforming Growth Factor-β
As mentioned above, TGF-β is one of the mediators responsible for AAMinduced fibrogenesis. It is a cytokine with multiple influences, responsible for cell
proliferation, differentiation, adhesion, migration and apoptosis of various cells types.[47]
It is produced from most cell types, including those of the immune system such a
neutrophils, macrophages, and dendritic cells.[48] TGF-β is a critical molecule in
pulmonary homeostasis: it blunts inflammatory response to injury and infection, while
also coordinating the wound healing process by upregulating matrix genes.[49] TGF-β is
produced as a latent precursor bound to latent associated protein (LAP), where it is
cross-linked to the ECM of most organs to be activated when necessary[50, 51]; when
activated, TGF-β attracts fibroblasts and induces them to produce a number of fibrotic
components, including collagen and fibronectin.[52, 53] It can be activated by cleavage
of LAP by a variety of proteases, such as thrombospondin, plasmin, and integrin β6, as
examples.[49, 54, 55] Once activated, the protein is free to move about the pulmonary
spaces and bind to the TGFβRII receptor.[56] When bound to its receptor, TGF-β
signals through a primarily Smad-dependent manner, as outlined in Figure1.1, to
upregulate matrix-associated gene production.[47]
TGF-β is necessary for pulmonary development – in early stages of growth it is
responsible for the formation of the architecture of the airways and alveolar sacs. [57] It
is also a necessary component of the normal immune response. It is activated late in
the response to infection in order to downregulate the production of inflammatory
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cytokines.[51] Activation of the inactive form is the primary means of regulation of TGFβ, and this is triggered by the upregulation of its activators, which are typically released
during hyperinflammatory states.[58] However, this is a molecule that must be
maintained in correct balance; too little TGF-β causes hyperinflammation, while too
much TGF-β results in lung fibrosis and scarring.[59, 60] When there is too much TGF-β
present post-development, the mechanisms that are crucial in forming the architecture of
the lung are re-initiated, leading to deposition of connective tissue where it is harmful. In
this way, TGF-β is upregulated in multiple models of lung repair; it is released by multiple
types of AAM (Table 1.1), and is significantly increased in models of bleomycin-induced
fibrosis [52, 61]. Other chronic inflammatory and fibrotic pulmonary diseases, such as
chronic obstructive pulmonary disorder (COPD) and idiopathic pulmonary fibrosis (IPF),
have reported increases in TGF-β mRNA and protein production as well.[62]
In IPF, TGF-β increases fibrosis accumulation. This appears to be promoting
activation and recruitment of fibroblasts that leads to the fibrotic characteristics of the
disease.[53] In lung biopsy samples from patients with advanced IPF,
immunohistochemistry analysis shows that TGF-β is localized to areas of dense fibrosis
and connective tissue deposition.[63] This occurrs in both bronchiolar epithelial cells
and in type II pneumocytes. These cell types showed hyperplasticity, which is
characteristic of the disease. Another study also evaluated biopsy specimens from
patients with IPF via immunohistochemistry.[64] Investigators found TGF-β not only in
epithelial cells, but also in myofibroblasts, indicating that both types of cells are being
induced to produce matrix proteins. In addition, the cells that stained TGF-β positive
persisted over a period of 14 days, while cells that stained positive for TNF-α diminished
over that time. Interestingly, the results showed an interaction of the interstitium and the
alveolar epithelium during IPF, based on TGF-β localization.
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Broekelmann, et al, went a step further in evaluating the localization of TGFβ.[65] This study showed that macrophages that stained positive for TGF-β production
by in situ hybridization and immunohistochemistry were localized to the site of activated
fibroblasts that were expressing high amounts of matrix proteins, including fibronectin,
procollagen, and smooth muscle actin. This demonstrated a direct correlation that cells
of the immune system, and not just cytokines, were involved in development of IPF and
the resulting matrix accumulation.
TGF-β appears to have similar effects in COPD. While the initial causes of IPF
are still unknown, COPD is primarily a disease caused by environmental exposure to
inhaled chemicals; most often those associated with cigarette smoke.[66] Most of the
damage caused by the chemicals is concentrated in areas of the small airways. In the
case of emphysema, an obstructive disease under the umbrella of COPD, the damage is
more generally located to the alveoli.[67] In all cases of damage, however, TGF-β
upregulation acts as a function of wound healing, leading to fibrosis, as a
consequence.[68] This has been demonstrated in several studies. TGF-β was
examined in subjects with or without COPD who underwent lobectomy for cancer;
subjects were either current or ex-smokers.[62] In the lung tissue specimens from
subjects with COPD, TGF-β mRNA was positively correlated with bronchial and
bronchiolar epithelial cells, while this correlation was not as strong in subjects without
COPD. The authors suggest that this increase correlated to the recruitment of mast
cells and macrophages to sites of damage, as TGF-β is known to be chemotactic.
Takizawa, et al, correlated TGF-β mRNA not only with COPD but also with smoking. [69]
This study compared subjects with COPD to healthy subjects who were smokers and
healthy subjects who never smoked. TGF-β mRNA was upregulated in smoking
subjects with and without COPD, and correlated positively with subjects’ duration of
smoking (in terms of pack-years). This suggests that TGF-β is directly increased as
12

damage from exposure occurs, and that it could be a major mechanism of fibrosis
buildup during disease.
TGF-β has also been investigated as a mitigating factor in CF pulmonary
disease. There is some evidence that TGF-β may have an interaction with the CFTR. A
study performed at University of California at San Francisco showed that TGF-β reduces
β2-adrenergic dependent chloride transport, resulting from CFTR reduced activity. This
appears to be acting in a cAMP-dependent manner.[70]
Importantly, TGF-β expression has been shown to be increased in patients with
CF compared to patients with a non-CF pulmonary exacerbation.[71] In this study that
enrolled patients with CF investigators found a correlation between high TGF-β protein
levels in BALF and reduced lung function. Investigators also demonstrated that TGF-β
levels were not different in patients colonized with P. aeruginosa compared to CF
patients who had not cultured this pathogen. An additional study from this group found
that levels of TGF-β in the plasma correlated to BALF TGF-β levels, and that plasma
TGF-β was actually increased in patients positive for P. aeruginosa colonization.[72]
Treatment for the infection decreased plasma levels of TGF-β, and post-treatment
measurements of TGF-β were inversely correlated with lung function. The implications
for TGF-β in CF become more interesting when polymorphisms are examined: a
phenotypic gene study in the Czech Republic showed that patients with CF who had
TGF-β concentrations at both high and low extremes in their lungs had the worst
outcomes.[73] Although the polymorphisms were not associated with lung function, they
were associated with other organ disease.
The studies summarized here demonstrate that TGF-β is of critical importance in
various diseases of fibrosis, including CF. It is a protein produced by with AAMs, which
have also been associated with diseases of fibrosis, as noted above. There is also
evidence that in the absence of TGF-β, presence of AAM is reduced.[74] This study will
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continue to investigate TGF-β in the development of fibrosis, in the context of P.
aeruginosa infection.

TGF-β
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Figure 1.4. Activation of the TGF-β Smad-dependent signaling pathway. TGF-β
isoforms binds to TGF-βRI and II coupled, which then phosphorylate Smad2.
Phosphorylated Smad2 binds Smad4, and the complex travels to the nucleus to bind to
a transcription factor and begin transcription of TGF-β dependent genes.

D. Matrix Metalloproteinase-9
In many of the aforementioned pulmonary diseases, TGF-β is linked with MMP
function.[42] TGF-β can suppress the production of these proteases that are produced
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by monocytes and macrophages, which could lead to a reduction in ECM turnover.[75]
This, in turn, could lead to clearance of ECM proteins before they are accumulated to a
degree that would lead to scar tissue and pulmonary function decline.’
One member of this family is MMP-9. It is a protease that is also known as
gelatinase B, as the first known function was to bind and cleave gelatin. Other
substrates have since been identified, including collagen IV, α1-antiproteinase, latent
TGF-β1, latent VEGF, fibrin, and fibronectin.[76, 77]. MMP-9 has similar activity to
another member of the family, MMP-2, also known as gelatinase A. Like TGF-β, these
proteases are produced in an inactive form, and are then activated among the tissues.
Activation of the pro-forms, or zymogens, is generally based on availability of substrates,
however, rather than other catalytic enzymes.[78] Once activated, the enzymes are able
to execute their main function of cleaving other proteins.
In the lung, MMP-9 is primarily involved in remodeling. Many types of cells can
produce this enzyme, including bronchial epithelial cells, alveolar type II cells,
fibroblasts, endothelial cells, and immune cells; neutrophils, macrophages, lymphocytes,
NK cells, and dendritic cells have all been shown to produce MMP-9.[79] There is
typically little to no MMP-9 in healthy tissue, but it is released quite readily upon injury.
[76] One function is that it appears to facilitate cell migration. The degradation of
collagen IV, a basement membrane protein, allows architecture to be changed in order
for immune cells to migrate to the site of inflammation.[80] It also allows for remodeling
of structure after or during inflammation for epithelial cells. [81]
One type of immune cell that produces MMP-9 in large amounts is neutrophils.
These cells produce MMP-9-filled granules during bone-marrow maturation and release
the granules during migration toward sites of inflammation.[79] Therefore, MMP-9 is
often associated with inflammatory diseases. For example, in ventilator-induced lung
injury, in which there is an influx of neutrophils, MMP-9 has been shown to be increased
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in response to ventilation.[82] Furthermore, this study showed that MMP-9 activity was
associated with neutrophil influx, as well as degree of acute lung injury. The
investigators also demonstrated that when MMP-9 was inhibited, this effect was
prevented, suggesting that MMP-9 may be promoting neutrophil influx in this model.
In a model of emphysema, the result of chronic inflammation, MMP-9 was again
associated with inflammation. Mice which had inactivation of the surfactant protein D
gene developed emphysema and had increased activity of MMP-9 compared with mice
that had function surfactant protein D.[83] MMP-9 has also been associated with
bronchiectasis, which is a result of chronic inflammation in the airways. In this
inflammatory disease, bronchial walls are destroyed, often as the result of damage by
neutrophilic-associated lytic enzymes. Among these were MMP-9 and MMP-8; these
two proteins were detected by immunostaining in bronchial biopsy specimens of subjects
with bronchiectasis, and were highly correlated with number of neutrophils present.[84]
This study provides evidence that excess MMPs may cause damage to the airways.
However because MMP-9 has the ability to assist in remodeling pathways, it is
also an important molecule in diseases of fibrosis. In a model of bleomycin-induced lung
fibrosis, MMP-9, as well as MMP-8, concentration was increased in the BAL of mice
treated with bleomycin.[85] In these same mice, hydroxyproline, a precursor of collagen,
was increased at day 14 post-administration. However, when the neutrophils were
depleted, MMP-9 concentrations were reduced, compared with that found in the
bleomycin treated mice. Conversely, hydroxproline was increased in the neutrophildepleted group, suggesting that the upregulation of MMP-9 in fibrotic processes assists
in turnover of the accumulation of fibrotic proteins. Also supportive of that notion, a
group of investigators showed that pro-MMP-9 secretion from macrophages is increased
by fragmented fibronectin.[77] When monocytes isolated from human peripheral blood
were incubated with TNFα and incubated with either native fibronectin or fibronectin
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degraded into specific fragments, the degraded fibronectin elicited more of a response
from the macrophages to produce pro-MMP-9.[77] Because MMP-9 can degrade
fibronectin directly[79], this data is likely indicative of a feedback mechanism, wherein
MMP-9 can be stimulated to continue to degrade ECM. This suggests a role for MMP-9
in controlling the buildup of fibrosis. It also suggests that moderate increases in MMP-9
concentrations may have positive outcomes, by degrading fibronectin before it
accumulates to cause scarring.
Lastly, MMP-9 has also been studied in patients with ventilator associated
pneumonia (VAP) who are infected with Pseudomonas aeruginosa. In these patients,
serial BALF samples were collected and analyzed for MMP-9, MMP-8, and tissue
inhibitor of metalloproteinases (TIMP)-1 concentrations. TIMP-1 is the natural inhibitor
of the MMPs, which circulates in order to counteract the activity of the proteases. Both
MMP-9 and -8 concentrations were significantly higher in the BALF of patients with VAP
compared with patients ventilated only for airway protection.[86] Patients were further
analyzed for microbiology profiles, to see if their cultures possessed type III secretion
system (TTSS) characteristics. The TTSS is the mechanism in P. aeruginosa that
secretes toxins that cause damage to the host. When analyzed this way, the authors
found that MMP-9 was increased in patients whose bacterial growth showed TTSS
positive characteristics, compared to patients whose bacterial growth was TTSS
negative. Lastly, patients with higher MMP-9/TIMP-1 ratios had a higher risk of death
compared to those with lower MMP-9/TIMP-1 ratios. Because there is more protease
compared to its inhibitor, this suggests that more MMP-9 activity, most likely in response
to more virulent bacteria, is detrimental to the outcome VAP patients.[86] The authors
suggest that proteases, such as MMP-9 and -8, are released more readily as the toxicity
level of the bacterial infections increases, causing heightened risk of airway damage and
death.
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MMP-9 also plays an important role in the pathophysiology of CF, a result that is
not surprising given the data underlining its importance in diseases of neutrophilic
inflammation, fibrosis, and P. aeruginosa pneumonia. Increases in MMP-9 production is
associated with occurrence of pulmonary exacerbation, airway breakdown leading to
remodeling, and in response to infection with Burkholderia cenocepacia in patients with
CF, all of which can decrease survival.[87-89] Sagel, et al, assessed induced sputum
samples from healthy controls and subjects with CF for levels of MMP-9 and TIMP-1.[90]
This study found that concentrations of both molecules were significantly higher in the
CF subject samples, as was the ratio of MMP-9/TIMP-1. MMP-9 was also negatively
correlated with FEV1, and therefore positively correlated with disease severity, in these
subjects. Lastly, both MMP-9 and TIMP-1 were positively correlated to neutrophil
counts, and levels of IL-8 in the sputum samples.
Another study examined lower airway secretions of subjects with CF, comparing
the results to subjects with non-CF acute respiratory failure(ARF) as the controls.
Gaggar, et al, showed that subjects with CF had increased active MMP-9
concentrations, while subjects with ARF had increased active MMP-8 concentrations in
samples taken from endotracheal suctioning. [19] The study went on to show that the
increase in CF MMP-9 activity is constitutive, while subjects with ARF had mostly
inactive, pro-MMP-9 forms of the enzyme in their samples. However, subjects with CF
had lower levels of TIMP-1 in their secretions than did the ARF subjects, and higher
MMP-9/TIMP-1 ratios. This indicates dysregulation, and potential hyperactivity of the
protease in the CF airways.
Lastly, Ratjen et al examined MMP-9 levels and their potential modulation by a
commonly used CF treatment.[91] In this study, the expected increases in MMP-9,
MMP-8, and TIMP-1 in BALF of subjects with CF compared with healthy controls were
demonstrated. However, when the concentrations of these three molecules were
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measured in BALF 18 months later, treatment with dornase alfa had reduced levels of all
three markers after compared to subjects not receiving the drug. Dornase alfa cleaves
the DNA that accumulates in the mucus of patients with CF[92]; it has been shown to
increase FEV1. This study suggests that preventing tissue destruction by MMPs may be
one of the ways in which this is being accomplished.
Taken together, previous study of MMP-9 shows its importance in the process of
fibrotic disease. Overabundance of MMP-9 in relationship to its inhibitor predisposes
toward damage and bronchiectasis, yet the protease is still necessary to turnover of
ECM proteins. However, whether this molecule is causing fibrosis by initiating the
damage that requires subsequent repair, or whether it is upregulated after fibrosis is
initiated in order to clear away the buildup of repair molecules is unclear.

E. Anti-inflammatory Therapy for CF
Patients with CF are treated using a number of different therapeutic approaches.
Mucolytics, such as dornase alfa (Pulmozyme) and acetylecysteine (Mucomyst) help to
decrease viscosity and clear away mucus. Oral, intravenous, and aerosolized
antimicrobial agents are used during exacerbations caused by infecting organisms and
routinely for bacterial clearance and suppression.[92] However, many additional
therapies for CF now focus on influencing the hyperinflammatory state of the immune
system. Inhaled and oral corticosteroids, used in a multitude of other disease states for
inflammation, are not actually recommended for CF.[92] While these drugs can be very
effective for chronic inflammatory disease states such as asthma, studies have shown
that decline in FEV1 is not improved in CF patients, nor are there decreases in
exacerbations in patients taking corticosteroids.[93, 94] In addition, patients with chronic
steroid use experienced glucose abnormalities, growth retardation, and cataracts.[95]
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Oral nonsteroidal anti-inflammatory drugs (NSAIDs) have also been studied in patients
with CF, mostly ibuprofen. This drug must be dosed significantly higher than typically
recommended, and must be given on a daily basis. Studies have demonstrated slowed
decreases in FEV1 compared to placebo controls, an effect that is dramatic for subjects
less than 13 years of age.[96] Yet no changes in hospitalizations rates, an indicator of
exacerbation, have been demonstrated. However, studies from this group also suggest
that sub-therapeutic levels of ibuprofen may actually exacerbate inflammation, and
therefore recommends pharmacokinetic monitoring for each patient. This
recommendation makes chronic treatment of ibuprofen difficult for many patients.
Another concern for long-term therapy with ibuprofen is the potential for renal damage
and gastrointestinal toxicity; the study done was not powered to detect these effects.
The limitations of these interventions leave a need for the development of effective antiinflammatory therapies to treat the hyper-immune response observed in CF.
The latest class of drugs to be examined for its anti-inflammatory effects in CF is
the macrolides. These antimicrobials target the 50S ribosomal subunit in bacteria, thus
disrupting protein translation. Azithromycin (AZM) is the macrolide that is most often
used, due to its reduced side effects, ease of administration, and broad spectrum.[97]
AZM has activity against mainly gram negative bacteria, but also atypical organisms, like
Legionella pneumonia, and some aerobic and facultative gram positive organisms, such
as S. pneumonia; however it has no bactericidal activity against P. aeruginosa or S.
aureus. [98, 99] While AZM is a common therapeutic agent used to treat bronchitis,
sinusitis, and other upper and lower respiratory infections, because of its spectrum of
activity it is ineffective in treating many of the types of infections that CF patients are
prone to. Instead, AZM is employed as a long-term therapy for its effects on the immune
system. AZM is extensively partitioned into the cells, leaving serum concentrations low,
and has a long half-life, which allows for daily or every other day dosing.[100] In this
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way, AZM is able to affect cell signaling of macrophages. These drugs, especially AZM,
are shown to have direct anti-inflammatory effects, including alterations in cytokine
production profiles and changes in NF-κB nuclear translocation.[101] AZM has minimal
adverse effects and has not been associated with the issues found when using
corticosteroids and NSAIDs for chronic treatment.
To that end, continuous treatment with AZM has now been studied in multiple
clinical trials. Subjects treated with AZM have increased FEV1, decreased pulmonary
exacerbations, and reported better quality of life compared to placebo controls.[50, 102]
The first study by Saiman, et al, recruited subjects with CF who were colonized with P.
aeruginosa.[50] Patients receiving AZM for 168 days reported higher increases in FEV1,
less incidence of exacerbation, and increased weight as compared to baseline at the
end of the study compared to patients receiving placebo. While antibacterial resistance
is a concern for this treatment, Saiman, et al, showed in this study that treatment with
AZM did not change resistance profiles in multiple bacteria compared to placebo control
subjects. The two groups had similar resistance rates of current infections and growth of
new infections at the end of the trial, including MRSA, suggesting that AZM does not
pose a significant threat toward inducing antibacterial resistance in this population.[50]
While AZM was initially studied in patients who were already infected with P.
aeruginosa, this group repeated their study in patients negative for P. aeruginosa
colonization.[103] Once again, they showed that AZM treatment over 168 days reduced
the risk of exacerbation compared to placebo. Here, AZM did not improve pulmonary
function in this subset, but this study, like the previous, showed no changes in
microbiology or in treatment-emergent microbiology. This data was important to show
that AZM is safe to use long-term in this cohort from a microbial resistance
standpoint.[103]
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Equi, et al, performed a 15-month crossover trial with AZM treatment in pediatric
patients with CF in 2002.[104] Subjects received AZM or placebo for six months,
followed by a two-month washout period, and then received the opposite therapy.
Results showed that subjects required fewer days of oral antibiotic therapy when on
AZM, suggesting AZM could reduce the incidence of exacerbations. Though this study
did not demonstrate a statistically significant effect on FEV1, it did show that FEV1
improved on AZM but returned to baseline at the end of a washout period. This provides
some justification for the chronic dosing of the drug. This study also showed no
differences in sputum bacterial densities, which is further support that AZM does not
affect microbial resistance. Importantly, there were no subjective reports of side effects,
and liver tests showed no evidence of toxicity. [104]
Finally, Wolter, et al, found that patients who received AZM for three months had
decreased number of IV antibiotic courses, as well as decreased total numbers of days
on IV antibiotic therapy. This complements the study done by Equi, et al, to corroborate
the evidence that AZM can reduce the number of exacerbations when given over the
long term. Subjects in this trial also reported significantly improved quality of life,
assessed by the Chronic Respiratory Disease Questionnaire.[105] Lastly, these
subjects had reduced levels of CRP, a general marker of inflammation.[104]
While AZM is not bactericidal against P. aeruginosa, there is some evidence that
it can affect the bacterium in other ways. Quorum sensing gene production, a regulatory
mechanism that allows the bacteria to coordinate growth, metabolism, and protein
production based on density or growth, is disrupted by AZM.[106] When sub-MIC levels
of the drug are added to bacterial cultures, organisms undergo reduction in quorum
sensing gene production and reduced motility. Also through disruption of quorum
sensing circuits, AZM blocks alginate and other biofilm component production and
therefore prevents biofilm to aid the survival of bacteria grown in vitro and in vivo.[107,
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108] This was demonstrated both with susceptibility assays in cell culture and in
pulmonary infection with P. aeruginosa in CFTR-/- mice. Interestingly, AZM has been
recently shown to affect some small RNAs upstream of the quorum sensing pathway,
adding complexity to the impact of the drug on the ability of the bacteria to
communicate.[109] Together, these data suggest that, while the drug may not be acting
directly to kill the bacteria in the CF population, long-term treatment may have some
overall benefit in disrupting the bacterium’s ability to maintain high-density function.

Azithromycin and Alternatively Activated Macrophages
Because AZM is utilized in patients with CF for its anti-inflammatory properties, it
is important to identify the effects of the drug on specific cells. Published work has
shown that AZM can affect the NF-κB inflammatory cascade in monocytes and bronchial
epithelial cells.[110, 111] However, these authors did not address how the monocytes
are affected once they become activated into macrophages. To extend these studies,
our lab demonstrated that AZM treatment alters surface marker expression and cytokine
production of macrophages; increasing MR, and decreasing CCR7. AZM treatment
increased the effector protein of AAMs, arginase, as well as switching the cytokine
profile from IL-12 to IL-10 producing, in vitro (Figure 1.5).[112] Together, these data
suggest that AZM is polarizing macrophages toward an alternatively activated
phenotype. This is confirmed further, by evidence that AZM increases arginase in vitro
and in vivo (Figure 1.6), and decreases iNOS, associated with CAM activity.[112]
Preliminary data from our lab also shows that AZM decreases IKK-β, a molecule in the
signaling cascade of the toll-like receptors. When phosphorylated, IKK-β releases NFκB to translocate to the nucleus and begin transcription of inflammatory proteins.
Importantly, in a study conducted by Fong, et al, IKK-β has also been shown to inhibit
Stat-1, and may be decreasing the CAM effector proteins in this way.[113]
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Our data, combined with this evidence of IKK-β/Stat-1 interactions, suggest that
this may be the mechanism by which AZM can alter the polarization of macrophages.
Furthermore, AZM could be resulting in full AAM function, upregulating ECM mediators
and components. If that is the case, and the AZM- polarized macrophages are
functioning to increase fibrosis, the implications could be important. As stated above,
there are quite a few studies showing the association between AAM and fibrosis
development in either mouse models or human disease. If patients with CF have
increased Th2-driven immune responses as their disease progresses, they have the
natural propensity to have increased numbers of AAM in their pulmonary spaces without
AZM treatment, an effect that our group also previously characterized and
published.[114] Adding another stimulus for AAM may not be beneficial in the long term.
Alternatively, the increased presence of AAM may inhibit the hyperinflammatory
response characteristic of the CF pulmonary response. The full effects of the drug on
the macrophage are unknown; therefore it is important to examine the full functionality of
the AZM-polarized macrophage for long-term safety implications.
To that end, in this project, we studied the pro-fibrotic potential of the AZMpolarized macrophage. This macrophage phenotype was examined for its effects on
other cell types and the immune response to P. aeruginosa in general. Because of the
AAM-like properties of the AZM-polarized macrophages, and the fibrotic properties of the
AAM, we proposed the following hypothesis for this project: AZM-polarized
macrophages contribute to fibrosis by increasing the production of TGF-β and
decreasing the production of MMP-9 in the context of P. aeruginosa infection.
As stated above, understanding the full mechanism of AZM is important. The
effects on the macrophage population could be wide ranging and could affect the way
the macrophages interact with other immune cell types. The following dissertation
examines this interaction in detail.
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Figure 1.5. AZM polarizes macrophages to an alternative phenotype in vitro.
Macrophages were treated with INF-γ, with or without AZM. After overnight incubation,
LPS was added for stimulation. In a), arginase activity was measured and normalized
per µg protein and per 104 cells. In b), IL-12 and IL-6 was measured from the
supernatants by CBA. Data is represented as mean ± SD. Data were analyzed via oneway ANOVA. Significance of < 0.05 is indicated with *.
© Copyright 2008, Oxford University Press. All rights reserved.

© Copyright 2010 American Society for Microbiology. All rights reserved.
Figure 1.6. AZM polarizes macrophages to an alternative phenotype in vivo.
Macrophages were treated with INF-γ, with or without AZM. After overnight incubation,
LPS was added for stimulation. Arginase activity was measured and normalized per µg
protein. Data is represented as mean ± SD. Data were analyzed via two-way ANOVA.
Significance of < 0.05 is indicated with *.
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Figure 1.7. How molecules of interest are altered in CF pathology. Arginase has been
shown to be increased in CF, reducing the amount of NO available to kill bacteria.[115]
TGF-β is increased in patients with CF compared to healthy controls, causing increases
of ECM products.[71] MMP-9 is increased in patients with CF compared to healthy
controls, resulting in increased airway damage.[90]

F. Project Overview
In order to determine whether AZM-polarized macrophages are affecting fibrosis
through TGF-β and MMP-9 production, we employed three approaches. First, we used
an in vitro co-culture system to examine the direct effects of AZM-polarized
macrophages on fibroblasts. Using this system, we were able to examine the resulting
fibrotic mediator production in response to stimulation with P. aeruginosa. This model
was used to examine cell-cell interactions and protein-protein interactions. We also
utilized inhibitors of molecules important in fibrosis mediation, in order to determine the
mechanisms by which AZM is affecting the macrophage’s impact on fibrosis. Secondly,
we use a murine model to examine the role of AZM-polarized macrophages in the
immune response to P. aeruginosa pneumonia. We studied the immune response
overall, as well as the interactions of the molecules identified as important from the cell
culture results, including MMP-9 and fibronectin. In this model, we were able to
establish a lasting infection, isolating P. aeruginosa from the mice as late as 14 days
after inoculation. We also utilized genetically-engineered mice to examine AZM activity
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and the importance of the AAM in both the response to P. aeruginosa infection and the
subsequent fibrosis development. Finally, this project incorporated a clinical study
involving subjects with CF. Sputum samples were collected from these patients, and
concentrations of fibrotic proteins were measured and correlated to inflammatory
markers and markers of alternative macrophage activation. These factors were
examined in patient groups stratified by both AZM therapy and P. aeruginosa infection.
Results from the human study give up insights not only to how AZM is affecting
macrophages in patients, but also which appear to be most important in terms of severity
of disease.
The overarching hypothesis for this project is that AZM-polarized macrophages
contribute to fibrosis by increasing the production of TGF- and decreasing production of
MMP-9 in the context of P. aeruginosa infection. Each approach to this study produced
complementary results that allow for a better understanding of the role of AZM-polarized
macrophages in the development fibrosis. The co-culture model showed increased
production of fibrotic mediators from cells treated with AZM, including TGF-β, MMP-9,
and fibronectin. When the mice infected with P. aeruginosa were examined, we found
that those treated with AZM had increased concentrations of MMP-9 and fibronectin in
the BAL, as well as increased accumulation of collagen. The human study underlined
the importance of the interaction between infection and AZM treatment, with increased
arginase and TGF-β production in the sputum of those subjects both receiving AZM and
positive for bacterial colonization. This study also highlighted important relationships
between these proteins and lung function.

Copyright © Susan Elizabeth 2012
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Chapter 2: Azithromycin-polarized macrophages increase fibrosis mediators in
co-culture with fibroblasts
A. Introduction
Alveolar macrophages are a component of the innate immune response, and
responsible for being first line of airway defense for pulmonary infections. The
macrophages that are involved in bacterial killing and clearance are classically activated;
these cells upregulate molecules such as inducible nitric oxide synthase (iNOS), which
produces nitric oxide. Nitric oxide, along with other products of CAMs, participates in
bacterial killing in the lysosomes.[26] These cells are traditionally activated by IFN-γ and
a microbial trigger, such as LPS. Conversly, AAMs function to coordinate debris
clearance, repair, and tissue remodeling.[116, 117] They produce arginase as a primary
effector protein, in direct contrast to iNOS, which metabolizes the same substrate, Larginine, to urea and L-ornithine, which can then be converted to proline and
polyamines. These molecules are then incorporated into collagen and fibronectin, key
components in extracellular matrix.[27] Further, arginase production has been
associated with TGF-β activation, which also increases fibrotic mediators.[41] This has
been shown in multiple models of pulmonary repair.[41, 45]
MMP-9 is a protease, released from multiple cells, which is able to assist in
turnover of the ECM by degrading proteins such as fibronectin and collagen.[75] In this
way, it is able to counteract the pro-fibrotic effects of TGF-β. However, TGF-β is able to
decrease expression of MMP-9 from monocytes, as a mechanism of reducing ECM
turnover.[118] Therefore, if AZM affects TGF-β, it is important to know if the drug will
affect MMP-9 as well. It is this set of effector proteins that this chapter’s work is focused
on.
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Previous work in our lab has shown that AZM is able to polarize macrophages
toward an alternatively activated-like phenotype. When macrophages were treated with
AZM in addition to LPS and IFN-γ, there was an alteration in the phenotype compared to
macrophages treated only with LPS and IFN-γ.[112] Macrophages which were treated
with AZM demonstrated significantly reduced production of the inflammatory cytokines
IL-6 and IL-12, as well as increased production of the anti-inflammatory cytokine IL-10.
These AZM-treated macrophages had a shift in surface receptor expression, with
increases in mannose receptor and CD23, and decreased expression of CCR7, a
protein profile that is indicative of alternative phenotype.[27] The cells treated with AZM
also produced decreased amounts of the CAM effector protein iNOS compared to the
cells treated with IFN-γ and LPS alone; the AZM-treated cells upregulated arginase, the
effector protein of the alternative macrophage phenotype. AZM was able to polarize
these macrophages toward the alternative phenotype even in the presence of the
classical cytokine IFN-γ[112]
This alteration of macrophage function may be the means by which this drug is
able to positively affect patient’s clinical outcomes.[114, 119] CAMs produce molecules
that are damaging the CF lung in response to the repeated and/or chronic infection in
these patients, and AAMs have been shown to directly inhibit these inflammatory
functions.[26, 32] However, as mentioned above, CF patients are already primed to
have an increase in AAMs, as they have increased concentrations of cytokines such as
IL-4 and IL-13.[22] This may be a compensatory protective mechanism as the disease
severity progresses, in an attempt by the body to minimize the danger. AZM-polarized
macrophages have not been evaluated for the effects that they may exert upon other cell
types involved in the remodeling process. Therefore, it was important to investigate not
only the anti-inflammatory response of the macrophage to the bacterium P. aeruginosa,
but also the effect of these AZM-polarized AAMs on other cell types. Fibroblasts are
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important in the lung during remodeling process, and are a major cell type involved in
the production of fibrotic mediators. Therefore, we chose to examine these two types of
cells in vitro in order to determine whether AZM-polarized macrophages are able to
induce production of fibrotic mediators from fibroblasts.
Lastly, we sought to determine a mechanism by which AZM affects the shift in
polarization in the macrophages. Previous work in our lab has identified alterations in
the NF-κB signaling cascade as a possible mechanism for the decreased inflammatory
cytokine production already mentioned.[112] One of the proteins altered in this cascade,
IKK-β, was identified as a potential target for AZM during the polarization of the
macrophage. To this end, we investigated whether the increase in fibrosis was also
occurring through this molecule.
For these experiments, macrophages and fibroblasts were co-cultured together,
according to the design in Figure 1 below. The effect of AZM in an environment that
would otherwise stimulate toward a CAM phenotype was studied. As discussed
previously, TGF-β and MMP-9 are both molecules that have been associated with
diseases in which fibrosis is a pathologic component.[40, 77] TGF-β signaling
upregulates fibrotic proteins, such as fibronectin, from fibroblasts,[65], while MMP-9 can
degrade these same molecules and result in ECM turnover.[85] These molecules have
also been associated with the AAM phenotype in a model of fibrotic disease.[42]
Therefore, we postulated that TGF-β and MMP-9 may be important molecules in the
mechanism of AZM’s effect on the macrophage. We hypothesized that AZM-polarized
macrophages induce ECM buildup during P. aeruginosa infection by increasing
production of TGF-β and MMP-9.
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Figure 2.1. Schematic of experimental methods used for the co-culture experiments.

B. Materials and Methods
Fibroblast/Macrophage Co-Culture System
The mouse cell lines NIH/3T3 and J774A.1 (ATCC, Manassas, VA, USA) were
used for the co-culture system. The NIH/3T3 line (ATCC #CRL-1568) is a fibroblast cell
line originally obtained from embryonic cultures of NIH Swiss mice.[120] The J774
(J774A.1, ATCC #TIB-67) cell line is an immortalized macrophage cell line derived from
BALB/cN adult mice.[121] Cells were grown in RPMI 1640 media (Invitrogen, Carlsbad,
CA, USA) supplemented with 5% fetal calf serum and 2x10-5M 2-mercaptoethanol at
37°C and 5% CO2. At time 0 of the experiment, NIH/3T3 cells were added to culture
treated 6 well plates at a density of 2.5 X 105 cells/ml, and allowed to incubate overnight.
The media was then removed and replaced with 5 mL of medium along with 2.5 X 105
J774 cells/5ml, and again allowed to incubate overnight. The next morning, cells were
stimulated by adding interferon-γ (R&D systems, Minneapolis, MN, USA) (IFNγ)
(100ng/mL) and 2.5 X 105 P. aeruginosa, of the strain PA39018, a non-biofilm producing
strain obtained from ATCC (Manassas, VA, USA). Certain wells were additionally
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treated with 30μM azithromycin (Sigma Aldrich, St. Louis, MO, USA) (AZM). The
optimal concentration of AZM had already been determined, based on dose response
studies, as 30μM is enough to elicit the maximum response of the drug – with regard to
arginase and mannose receptor expression. Cells were incubated and harvested after
0, 6, 12, 24, or 48 hours. At these time points, cells were dislodged via scraping and
centrifuged, and 1mL of supernatant was saved for collagen and TGF-β analyses. Cells
were washed, enumerated with trypan blue staining to assess viability, and aliquots were
taken for the arginase activity assay and qRT-PCR. Supernatants and cells were frozen
at -80°C for later analysis. Cells were additionally suspended in 150μl of RIPA buffer
with Roche Mini-tablet protease inhibitor cocktail for lysis upon thawing, and aliquots of
cells were frozen in RNAlater (Applied Biosystems, Foster City, CA, USA).

Inhibitor Experiments
In a subset of experiments, neutralizing antibodies and/or small molecule
inhibitors were used to mechanistically investigate the role of effector proteins in the
fibrosis process and the impact AZM has on these processes. Materials used included:
S-(2-boronoethyl)-L-cysteine (BEC), used at 500μM, was utilized to inhibit arginase
activity. TGFβ-1,2,3 neutralizing antibody (R&D systems, Minneapolis, MN, USA) was
used at 0.25μg/mL, as recommended by the company. MMP-9 inhibitor SB 3CT (Enzo
Life Sciences, Farmingdale, NY, USA), was used at 600nM, which had been determined
by other groups to be the concentration to specifically block MMP-9 and no other MMPs.
[122] Lastly, the IKKβ inhibitor IKK16 (Tocris Biosciences, Ellisville, MO, USA) was used
at 100nM, which was determined through previous experiments to optimally inhibit
arginase production by the macrophages.
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Arginase Activity
Arginase activity was quantified by measuring the conversion of L-arginine to
urea [123]. 10mM MnCl2 in 50mM Tris-HCl was added to the lysed sample and the
mixture was then incubated at 55°C to activate the arginase enzyme. L-arginine was
then added and samples were incubated overnight at 37°C. Each reaction was
terminated by the addition an acid solution. The colorometric indicator 9% alphaisonitrosopropiophenone (ISPF) in 100% ethanol was then added to each tube, heated
to 95°C, and the OD of each sample was read using a 490nm filter. Readings were
compared to a standard curve of known urea concentration. One unit of arginase
activity converts 1μmole of L-arginine to urea per minute. Values were normalized to
total protein concentration as assayed by the bicinchoninic acid protein assay (BCA)
(Pierce Biotechnology, Rockford, IL, USA).

TGF-β Activity
Active TGF-β in cell co-culture supernatants were analyzed by ELISA using the
TGFβ1 Emax ImmunoAssay System (Promega, Madison, WI, USA). Samples were
diluted in PBS per manufacturer’s instructions. Plates were coated with a monoclonal
antibody specific for bioactive TGFβ, and samples were added to the wells along with a
standard curve prepared using supplied TGFβ1 standard. Polyclonal anti-TGFβ1
antibodies were applied, followed by washing and incubation with horseradish
peroxidase conjugate. Development solution was applied to the samples, and the OD
readings were obtained at 450nm and compared to the TGFβ standard curve to find the
concentration of the active form of TGFβ in each test sample, then normalized to cell
count.
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qRT-PCR
RNA was isolated using RNeasy mini kits (Qiagen, Valencia, CA, USA) and
quantified using a Nanodrop 2000 (Thermo Scientific, Wilmington, DE, USA). Reverse
transcription was performed on equal amounts of RNA utilizing Taqman Reverse
Transcriptase Reagents (Applied Biosystems, Foster City, CA, USA) according to
manufacturer’s protocols. Quantitative real-time PCR was initiated utilizing Taqman
gene expression arrays for murine Tgfb, MMP-9, and GAPDH using an ABI Prism 7000
(Applied Biosystems, Foster City, CA, USA).

ELISA assay
Concentrations of effector proteins of interest in cell culture supernatants were
quantified by indirect ELISA. Samples were diluted in coating buffer and incubated at
4°C overnight for adherence to the ELISA plate. Wells were blocked, then incubated
with antibodies specific to MMP-9 (Abcam, Cambridge, MA, USA) or fibronectin (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA), followed by an anti-rabbit HRP
conjugated secondary antibody (Millipore, CA, USA). Wells were analyzed by OD
reading at 450nm, using OptEIA detection reagents (BD, CA, USA). Readings were
compared to a standard curve using MMP-9 or fibronectin recombinant protein.

Western Blot
Cell supernatants or cell lysates were run with β-mercaptoethanol, in denaturing
conditions, on 10% SDS-PAGE gels, and then transferred to PVDF membrane at 100V
for 1 hour. Membranes were blocked in 5% dry milk or bovine serum albumin (BSA), in
the case of phospho-antibodies in TBS for at least four hours. Primary antibodies were
diluted 1:1000 in 1% dry milk or BSA in TBS, and incubated overnight. Blots were
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washed and incubated for two hours at room temperature in secondary-HRP conjugate
at a 1:4000 dilution. Signal was detected using Pierce ECL Western Blotting Substrate
(Thermo Scientific, Rockford, IL, USA). Primary antibodies used were specific for Smad2
and pSmad2 (Cell Signaling Technology, Boston, MA, USA) and Collagen I and
Collagen III (Abcam, Cambridge, MA, USA). Secondary antibodies used were goat antirabbit HRP conjugated (Millipore, CA, USA), and goat anti-mouse HRP conjugated (BD
Pharmingen, San Diego, CA, USA).

Statistical Analysis
Results are reported as mean ± SD and compared using GraphPad Prism
(GraphPad Software, La Jolla, CA, USA). Data were compared via one- or two-way
ANOVA where appropriate, followed by Bonferroni’s post-test for individual comparisons.
Differences were deemed statistically significant at a p value <0.05.

C. Results
Arginase Activity
The first parameter analyzed in the co-culture system was arginase. Previously
we have shown that azithromycin can polarize macrophages exposed to IFN-γ to display
characteristics of alternative activation when stimulated with LPS isolated from E.
coli.[112] We observed a significant increase in arginase concentrations in cell lysates
after 24 (p<0.01) and 48 (p<0.01) hours of bacterial stimulation in cells treated with
azithromycin, suggesting an increase in alternatively activated macrophage polarization
(Figure 2.2a). Arginase concentrations predictably decreased when the organism was
introduced, as this shifts macrophages toward a pro-inflammatory state. Exposure to
azithromycin caused stabilization in this decrease in arginase production, so that by 24
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hours the concentration of arginase rebounded to a significantly higher level compared
to the control wells. Furthermore, when assessed with Trypan blue staining, there was
no statistically significant impact upon cell number or viability between azithromycintreated and the control cells (Figure 2.2b). Therefore, this suggests that azithromycin is
able to polarize macrophages to an alternative-like phenotype in the presence of
fibroblasts when stimulated with P. aeruginosa. This data confirms that the drug exerts
similar effects on macrophage polarization using this co-culture design that we reported
previously for J774 macrophages cultured alone. While the differences in arginase
production are small, data discussed later in this chapter indicate the they are likely
biologically relevant.

Figure 2.2. Azithromycin increases arginase production in macrophages when cocultured with fibroblasts. NIH/3T3 and J774 cells were cultured together overnight with
IFNγ with or without 30μM azithromycin (AZM), and stimulated the following day with P.
aeruginosa (PA). (a) Cells were harvested at 0, 6, 12, 24, and 48 hours, and arginase
activity, a measure of arginase concentration, was assessed in cell lysates. (b) Cell
viability was determined using Trypan blue staining and manual counting. AZM does not
significantly affect cell viability, and does not appear to be cytotoxic at 30μM. Samples
were run in triplicate, and data is shown as mean ± SD. Data is representative of 3
replicated experiments, and was analyzed using one-way ANOVA with Bonferroni’s
post-test. ** indicates a p value of < 0.01. [124]

TGF-β
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Because arginase and TGF-β have been correlated in models of pulmonary
fibrosis, [41, 125] we measured active TGFβ concentrations in the co-culture
supernatants, expecting an arginase-induced increase in production of TGFβ from the
alternatively polarized macrophages. Supernatants from co-culture conditions were
measured for TGF-β activity using the TGF-β1 Emax ImmunoAssay System (Promega,
Madison, WI, USA). Samples were run neat to determine endogenous active TGF-β and
acid-treated, to determine the amount of total TGF-β present. Total concentrations were
increased at 48 hours (p < 0.01) in cells treated with AZM (Figure 2.3a). Active TGFβ
concentrations in the supernatants were increased in the azithromycin-treated group,
Figure 2.3b, after 24 and 48 hours of stimulation as compared to baseline (with p values
<0.05 and < 0.01 respectively). Cells treated with IFN-γ and LPS had concentrations of
active TGFβ that fell below baseline by 48 hours after stimulation.
When the ratio of active/total TGF-β is plotted over time, AZM treated cells had
higher ratios compared to controls at 12, 24, and 48 hour timepoints (Figure 2.3c). The
difference over time comparing each treatment had an overall p value of 0.01. This
shows that the TGF-β that is present is activated more readily in the cells that had the
additional treatment of AZM.
In order to determine if AZM was only affecting activation, as opposed to
production, of TGFβ, we additionally assessed Tfgβ gene expression via qPCR over
time after P. aeruginosa stimulation (Figure 2.3d). Relative to time 0, Tfgβ mRNA
expression at 6 hours increased to a higher degree in the azithromycin-treated cells than
that observed in the absence of azithromycin. Following this, there was a downregulation of Tfgβ expression in both groups. The azithromycin-treated cells maintained
higher levels of mRNA throughout the experiment, although differences did not reach
statistical significance. This result, in conjunction with higher activated TGFβ
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concentrations (Figure 2.2b), indicates that azithromycin is likely affecting production of
the protein, but does not rule out the possibility that in vitro activation is also influenced.
Because arginase and TGF-β have both been increased in other studies of AAM
[45], we wanted to determine whether the effect on TGF-β activation was a result of the
increased arginase production induced by AZM treatment. To do this we utilized the
small molecule inhibitor BEC, which has the ability to inhibit arginase activity.[126]
When BEC was added to the co-culture at a concentration of 500μM, total TGF-β
concentrations were not changed by arginase inhibition (Figure 2.3e). However,
activated TGF-β concentrations induced by AZM were reduced in cells treated with BEC
(Figure 2.3f). As expected, the cells treated with IFN-γ, LPS, and AZM had increased
concentrations of active TGF-β at the 24 hour timepoint, p < 0.05, as in the previous
experiments. The result of this experiment confirms previous studies associating
arginase and TGF-β in models of pulmonary injury and repair, although other studies
have not employed the use of arginase inhibition. Altogether these data show that AZM
alters TGF-β mRNA transcription as well as protein translation and activation, and that
this is dependent upon the ability of AZM to increase arginase.
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Figure 2.3. Azithromycin increases active TGF-β and Tgfβ mRNA in the co-culture
system. Macrophages were co-cultured with fibroblasts and treated with IFNγ overnight
then stimulated with LPS in the presence or absence of azithromycin (AZM). Cells and
supernatants were collected at hours 6, 12, 24, and 48 after the addition of LPS. (a)
Total TGFβ concentrations in the culture supernatant were measured by the TGF-β1
Emax ImmunoAssay System. (b) Activated TGF-β concentrations in the culture
supernatant as measured by TGFβ1 Emax ImmunoAssay System are graphed over time
for the azithromycin treatment and non-treatment groups. (c) Ratios of active to total
TGF-β were determined, normalized as compared to time zero, and graphed over time.
(d) qPCR analysis of Tgfβ mRNA was normalized to GAPDH expression in each sample,
and then normalized to expression of Tgfβ at time zero. (e) Total TGF-β concentrations
and (f) active TGF-β concentrations were measured in the same conditions as the upper
graphs, but with the additions of the arginase inhibitor BEC. Data was analyzed using
two-way ANOVA with Bonferroni’s post-test. Significance is indicated for p values < 0.05
(*), < 0.01 (**), and < 0.001 (***), and p < 0.05 overall between groups (†).[124]
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MMP-9
MMP-9 is a protease that functions as an effector important in the turnover of
ECM through its ability to cleave fibronectin and collagen. It is also capable of directly
activating TGF-β.[76, 77, 127] This is accomplished by cleaving away TGF-β from its
latent protein while still bound to the matrix, at which point TGF-β is released for
downstream initiation of fibrogenesis.[55] Further, MMP-9 is capable of directly
degrading fibronectin, collagen III, and collagen IV.[76] Other macrolides, notably
erythromycin, have been shown to cause reduced levels of MMP-9 protein production,
making it important to study the effect of AZM on this molecule as well.[128] Therefore,
we examined MMP-9 using our macrophage/fibroblast co-culture experiment.
Macrophages and fibroblasts were co-cultured in the presence or absence of P.
aeruginosa, azithromycin, and cytokine treatment (IFN-γ or IL-4/IL-13), and supernatants
were collected 4 hours after exposure to the bacteria. Figure 2.4a shows that MMP-9
secretion was significantly increased at 4 hours by the addition of azithromycin (p
<0.001), even in the absence of cytokine treatment. Cells exposed to IFN-γ, P.
aeruginosa, and azithromycin produced concentrations of MMP-9 that were significantly
higher than cells treated with azithromycin alone (p <0.01), the CAM control condition of
IFN-γ plus P. aeruginosa (p <0.01), and the AAM control condition of IL-4/13 plus P.
aeruginosa (p<0.01). To further examine the modulation of MMP-9 expression in the
presence of azithromycin, the co-culture was then treated with conditions to induce a
CAM phenotype (IFNγ plus P. aeruginosa), both with and without azithromycin, and
analyzed over time. While cells began with similar levels of MMP-9 in the supernatants,
by 12 hours the concentration had dropped to levels that would be maintained through
72 hours (Figure 2.5a). The steady-state level of MMP-9 was significantly higher in the
cells treated with azithromycin. A similar trend was found when mRNA expression of
MMP-9 was determined under these conditions at earlier timepoints. Azithromycin
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treatment prevented the decrease in MMP-9 mRNA expression over time in the first 6
hours of cells treated with IFNγ and P. aeruginosa (Figure 2.5b). Taken together, these
results suggest that while azithromycin eliminated the transient decrease in MMP-9
production induced by the bacterium, the production to degradation ratio of MMP-9 was
thereafter maintained between the 2 conditions. We then examined the impact of
azithromycin exposure upon MMP-9 secretion from each individual cell line. The drug
dramatically increased the concentration of MMP-9 in the supernatant of the J774
macrophages, with a statistically significant difference at the 24 hour timepoint (Figure
2.5c). While production of MMP-9 from the fibroblast cell line was high (Figure 2.5d),
results were inconsistent across experimental timepoints as to the impact of
azithromycin directly on this cell type. These results suggest that the ability of
azithromycin to act requires interaction between these 2 cell types.

Figure 2.4. Azithromycin increases MMP-9 protein concentration. (a) Macrophages
were co-cultured with fibroblasts and treated with INFγ, IL-4/IL-13, or media alone
overnight. At time 0, azithromycin and/or P. aeruginosa (PA) were added, and the cells
were incubated for 4 hours. Supernatants were collected to measure MMP-9 protein
concentrations by indirect ELISA. Data was analyzed with one-way ANOVA with
Bonferroni’s post-test. Significance is indicated for p value < 0.001 (***).
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Figure 2.5. Azithromycin increases MMP-9 protein and mRNA expression. (a) Coculture cells were treated with IFNγ overnight and stimulated with PA in the presence or
absence of azithromycin (AZM). Cells and supernatants collected at hours 0, 6, 12, 24,
and 48. Supernatants were analyzed for MMP-9 protein concentration via indirect
ELISA. (b) Co-cultured cells were treated as in (a), but harvested at earlier timepoints to
measure mRNA for MMP-9. Cells were collected at timepoints 0, 15 min, 30 min, 1
hour, 3 hours, and 6 hours after the addition of PA, to determine the impact of
azithromycin treatment. Single cell controls were treated similarly to measure MMP-9
concentration in (c) J774 macrophages alone and (d) NIH3T3 fibroblasts alone. All data
was analyzed with two-way ANOVA with Bonferroni’s post-test. Significance is indicated
for p values < 0.05 (*), < 0.01 (**), and < 0.001 (***), and p < 0.05 overall between
groups (†).

Fibronectin
Fibronectin is a protein incorporated into the ECM during the process of
fibrogenesis, remodeling, and scar formation. TGF-β has been shown in other models to
increase the production of fibronectin [129]. Therefore, fibronectin concentrations were
examined as an endpoint for ECM increase in the co-culture model. While fibronectin
42

was measured in the supernatant samples, it was found to be already incorporated into
the ECM in the tissue culture plate, which was then spun down with the cell after tissue
harvest. Fibronectin was therefore measured with the cellular lysates preparations. At
specified timepoints, cells were harvested from tissue culture wells, pelleted via
centrifugation, and then lysed. Fibronectin was then quantified by indirect ELISA and
normalized to total protein concentration for each condition. Upon examination in the cocultured cells over time, significantly higher fibronectin concentrations were observed at
12 and 24 hours after stimulation with LPS in cells exposed to IFN-γ plus azithromycin
as compared to IFN-γ alone (p<0.001 and p<0.05, respectively, Figure 2.6a). Most of
the fibronectin in the cultures was found aggregated within the cell pellet, as opposed to
suspended in the supernatant, suggesting that fibronectin had already been incorporated
into the matrix component in the extracellular portion of the wells. The drug had no
effect on fibronectin concentration when either J774 or NIH/3T3 cells were separately
cultured and stimulated with LPS (Figures 2.6b and c). This data suggests that
azithromycin is affecting the control that the macrophages exert upon the fibroblasts in
the model. Furthermore, the addition of BEC reduced the increase in fibronectin
production induced by AZM (Figure 2.6d). This demonstrates that the increase in
arginase caused by addition of AZM is stimulating fibronectin upregulation, likely through
TGF-β activation.
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Figure 2.6. Azithromycin increases fibronectin concentration. Macrophages and
fibroblasts were co-cultured and treated with IFNγ and LPS, with or without 30μM
azithromycin (AZM) from time zero. Cells and supernatants were collected at hours 0, 6,
12, 24, and 48 hours after stimulation. (a) Fibronectin concentration in the cell pellet, as
a measure of protein incorporated into the matrix, was determined by indirect ELISA and
depicted over time. Macrophages (b) or fibroblasts (c) cultured alone and treated as in
(a) with fibronectin concentration shown over time post-stimulation with LPS. Fibronectin
concentration is also decreased with the addition of the arginase inhibitor BEC (d).
Results are normalized to μg protein in each sample. All data was analyzed with twoway ANOVA with Bonferroni’s post-test. Significance is indicated for p values < 0.05 (*),
< 0.01 (**), and < 0.001 (***), and p < 0.05 overall between groups (†).[124]
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TGF-β Neutralization
Because TGF-β has the ability to increase the production of ECM components,
we hypothesized that the effect of AZM on fibronectin was caused by the drug’s ability to
increase active TGF-β concentrations. Therefore, we conducted a TGFβ neutralization
experiment to determine if loss of activity would affect fibronectin production from the cocultured cells. The anti-TGFβ antibody utilized for this purpose selectively binds to the
activated form of the protein only. The neutralizing antibody was added to select wells of
co-cultured cells at the same time as LPS. Fibronectin and MMP-9 concentrations were
again assessed in the co-culture cell pellets and supernatants, respectively, over time.
While fibronectin concentrations were increased by azithromycin at 24 and 48 hours
compared to the control condition (p <0.001 and p < 0.05, respectively, Figure 2.7a), the
addition of anti-TGFβ antibody resulted in fibronectin concentrations that were nearly
identical between the treatment groups, ablating the effect of the drug (Figure 2.7b).
MMP-9 concentrations again decreased over time after stimulation with LPS, with
azithromycin causing MMP-9 concentrations to stabilize at a higher level than that of the
control condition (Figure 2.7c). The addition of the TGFβ-blocking antibody did not
change the impact of azithromycin treatment on MMP-9 concentration, as the MMP-9
levels in the supernatants mirrored what was observed in the wells with functional TGFβ
over time (Figure 2.7d). To ensure that the neutralizing antibody was indeed effective in
blocking TGFβ function, we performed a Western Blot to determine the impact of
neutralization on Smad2 activation. Smad2 is the main cell signaling molecule that is
phosphorylated when TGFβ binds to its receptor. Indeed we observed that Smad2
phosphorylation was inhibited by the addition of the neutralizing antibody (Figure 2.7e).
Taken together, these results suggest that the ability of azithromycin to impact MMP-9
concentration is independent of its effect on TGFβ activation, while the drug’s ability to
increase fibronectin concentration does rely on increases in TGFβ activation.
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Figure 2.7. TGF-β neutralizing antibody reverses the ability of azithromycin to affect
fibronectin but not MMP-9. Macrophages and fibroblasts were co-cultured, treated with
INFγ, and stimulated with P. aeruginosa (PA), with or without azithromycin (AZM). Cells
and supernatants were harvested over time to measure fibronectin with (a) and without
(b) the addition of TGFβ neutralizing antibody by indirect ELISA. MMP-9 concentrations
were measured in culture over time with (c) and without (d) the addition of TGFβ
neutralizing antibody by indirect ELISA. (e) TGFβ-neutralizing antibody’s effect upon
phosphorylation of Smad2. Smad and pSmad expression at 0 and 48 hours of culture
(with β-actin as a loading control) in cells co-cultured with LPS, IFNγ, and azithromycin.
Significance is indicated for p values < 0.05 (*), < 0.01 (**), and < 0.001 (***), and p <
0.05 overall between groups (†).
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Collagen
In addition to fibronectin, TGF-β can coordinate the production of the ECM
protein collagen.[129] For that reason, we also examined the amounts of collagen I and
III by Western blot to determine whether AZM-induced changed in TGF-β activity would
influence collagen production in the co-culture. We hypothesized that AZM would have
the same effect on the different forms of collagen, increasing their production as it did
fibronectin. However, western blot analysis determined that collagen I was actually
decreased by the addition of AZM when compared to cells that only received IFN-γ and
LPS. Additionally, the TGF-β neutralizing antibody did not affect the signal detected
(Figure 2.8a). Likewise, when AZM was added to the co-culture, collagen III
concentration was not altered compared to cells that were treated with IFN-γ and LPS
alone. However, when TGF-β neutralizing antibody was added to INF-γ, LPS, and AZM,
the amount of collagen III was increased in cell lysates (Figure 2.8b), suggesting that
TGF-β signaling may be causing a decrease in collagen protein production in the coculture system.

Figure 2.8. The effect of AZM and TGFβ-neutralizing antibody upon collagen I and
collagen III expression. Western blots of collagen I (a) and collagen III (b) expression at
0 and 48 hours of culture in cell lysates co-cultured with LPS, IFN-γ, and azithromycin
and TGF-β neutralizing antibody, as indicated below. Results are representative of
multiple experiments.
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MMP-9 Inhibition
Because the increase in MMP-9 concentrations was not dependent on TGF-β as
demonstrated in the TGF-β neutralizing experiments, we hypothesized that AZM may
actually be increasing MMP-9 first, which is then activating TGF-β directly. MMP-9 has
been shown to have this ability. [127] In order to determine if this is the case, an MMP-9
inhibitor, SB3CT (Enzo Life Sciences, Farmingdale, NY, USA), was added to the coculture at 600nM, which is a concentration specific for inhibiting MMP-9. [122] In these
experiments, when the levels of active TGF-β were measured by the TGF-β1 Emax
ImmunoAssay System, there was no decrease in TGF-β activation with MMP-9
inhibition, as would be expected if our hypothesis was correct. In fact, TGF-β activation
was even higher in those cells treated with the MMP-9 inhibitor added, at the 48 hour
timepoint Figure 2.9b Further, fibronectin concentrations were decreased with the
addition of the MMP-9 inhibitor, at 24 and 28 hours, (p < 0.0001 and < 0.001,
respectively, Figure 2.9c). This is the opposite result expected, considering that
activated TGF-β is increased in the same conditions, and data above has shown that
fibronectin is directly dependent on TGF-β. The data shows that MMP-9 is not the
major mechanism by which TGF-β is being activated in this co-culture system, but also
suggests that MMP-9 may actually be involved in some signaling mechanisms whereby
AZM is increasing production of fibronectin in concert with activated TGF-β.
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Figure 2.9. MMP-9 inhibitor reverses ability of azithromycin to increase fibronectin but
does not inhibit activation of TGF-β. Macrophages and fibroblasts were co-cultured,
treated with INFγ, and stimulated with LPS, in the presence or absence of azithromycin
(AZM) 30μM. Cells and supernatants were harvested over time to measure fibronectin
with (a) addition of the MMP-9 inhibitor SB3CT by indirect ELISA. Likewise, TGF-β
activity was measured over time with (c) addition of the MMP-9 inhibitor SB3CT using a
TGF-β1 Emax ImmunoAssay System. Significance is indicated for p values < 0.01 (**),<
0.001 (***), and < 0.0001 (****).
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IKKβ Inhibition

Figure 2.10. Activation of the NF-κB signaling cascade. LPS binds to TLR4, eventually
leading to activation of the IKK complex. Upon activation of the IKK complex, it
phosphorylates IκB, leading to the destruction of IκB. IκB is bound in its resting state to
NF-κB, preventing it from translocating to the nucleus of the cell. When NFκB
translocates to the nucleus, it binds to DNA leading to the transcription of genes
associated with inflammation. [124]
While the experiments utilizing the TGF-β neutralizing antibody and the MMP-9
inhibitor identified fibrotic mechanisms affected by AZM, we also wanted to investigate
the mechanism by which the drug affects macrophage polarization. It has been shown
that AZM has anti-inflammatory affects through decreased NF-κB signaling and
subsequent downregulation in inflammatory cytokine production.[101, 111] Yet these
studies do not investigate the entire NF-κB signaling cascade. Previous work in our lab
has shown that AZM alters multiple proteins in this signaling cascade. When TLR-4 is
stimulated by LPS, IKKβ is phosphorylated, causing phosphorylation of IκB, which
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ultimately allows NF-κB to translocate to the nucleus to initiate transcription of
inflammatory cytokines (Figure 2.10). Treatment with AZM decreases NF-κB activation
over time, while increasing IKKβ protein production. These changes are most dramatic
at the 10min timepoint post LPS-stimulus, as detected by protein concentration on
Western blot. Importantly, IKK-β has been demonstrated to exhibit cross-talk with the
Stat-1 pathway, decreasing Stat-1 phosphorylation.[113] This could have important
implications as to the reason why AZM alters the polarization of macrophages.
Therefore, we hypothesized that this is the mechanism by which AZM is affecting
macrophage polarization.
To confirm this hypothesis, we added the IKKβ inhibitor, IKK16, to macrophages
and fibroblasts. IKK16 is a small molecule inhibitor with specificity to the beta form of
IKK. Inhibition of IKKβ will result in inhibition of NF-κB downstream (Figure 2.10), by
reduced degradation of IκB. Previously, we had identified a target concentration for
IKK16. We had found that when the cells were treated with either IFN-γ and AZM, or IL-4
and IL-13, and stimulated with LPS, the addition of IKK16 blunted the increase in
arginase production induced by AZM when added to cells treated with INF-γ and LPS.
IKK16 was unable to block arginase upregulation in cells treated with IL-4/13, the
traditional way to stimulate the alternative macrophage.[27] Therefore, IKK-β inhibition
appears to be blunting the effects on arginase only through AZM, which strongly
supports our hypothesis that IKK-β is involved in the mechanism by which AZM shift
macrophage polarization.
To expand our investigation of this mechanism, we hypothesized that the
inhibition of macrophage polarization by IKK16 would also inhibit downstream fibrosis
development in the co-culture system. Therefore, the inhibitor was incubated with first
fibroblasts alone, and then the cells in co-culture, with cells treated with IFN-γ, AZM, and
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stimulated with LPS. Fibroblasts alone (Figure 2.11a) did not show an increase in
arginase activity in response to AZM until after 48 hours of exposure. This was
significantly different than the response from macrophages, which began to increase
arginase production while exposed to AZM in response to LPS stimulation within 6
hours. However, the increase of arginase production in fibroblasts was blunted by the
addition of IKK16. Co-culture cells (Figure 2.11b) had increases in arginase activity after
24 and 48 hours of incubation when treated with IFN-γ, LPS, and AZM compared to cells
treated with IFN-γ and LPS alone; IKK16 added to cells treated with AZM achieved a
statistically significant reduction in arginase activity at both 24 and 48 hours (all p values
< 0.0001). This suggests that increasing IKKβ activation likely plays a role in the
mechanism by which AZM is affecting these cell types.

Figure 2.11. Arginase activity in the presence of an IKKβ inhibitor. NIH3T3 fibroblasts
were cultured alone (a), and J774 macrophages were co-cultured with NIH3T3
fibroblasts (b), and both were stimulated overnight with IFN, AZM, and the IKKβ inhibitor
IKK-16. Cells were then stimulated with LPS up to 48 hours. Cells were then lysed, and
lysates were utilized for the arginase assay. Statistical analysis was performed with a
one way ANOVA with Bonferroni’s post-test. Arginase samples were run in triplicate,
and data represents mean ± SD.
To determine if downstream markers of fibrosis were reduced by the inhibition of
IKKβ, TGF-β activation, and MMP-9 and fibronectin concentrations were measured in
the co-culture treated with IKK16. Both TGF-β total concentrations and activation were
increased by addition of AZM to IFN-γ and LPS, but this effect of AZM was blocked at 24
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hours (Figure 2.12a,b), by the addition of the inhibitor of IKK-β, compared to cells that
were not exposed to inhibitor (Figure 2.12a,b), although this trend did not hold true at 48
hours. The concentration of MMP-9 was increased by AZM at 24 hours (p < 0.0001), an
effect that was again blocked by IKK16. Although the level of MMP-9 was not increased
by AZM at 48 hours compared to the control conditions, the concentrations of MMP-9 in
the sample treated with AZM+IKK16 were lower than the concentration in the condition
with only AZM (p < 0.0001). Fibronectin production was not increased by AZM until 48
hours of exposure, at which point the addition of IKK16 blunted the effect of AZM (p <
0.05). These data taken together suggest a mechanism by which AZM is acting through,
but identifies a pathway by which this may be occurring, and reverses the effect by the
addition of an inhibitor.

Figure 2.12. IKK16 inhibits TGF-β activation and MMP-9 and fibronectin increases
induced by AZM. Macrophages and fibroblasts were co-cultured, treated with INFγ, and
stimulated with LPS, in the presence or absence of azithromycin (AZM) 30μM. Cells and
supernatants were harvested over time to measure TGF-β total (a) and active
concentrations (b) by TGF-β1 Emax ImmunoAssay System , and MMP-9 (c) and
fibronectin (d) by indirect ELISA, with an without the addition of the IKKβ inhibitor IKK16.
Significance is indicated for p values < 0.05 (*) and < 0.0001 (****).
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D. Conclusions
Several important conclusions can be drawn from the data presented in this
chapter. It had been demonstrated that AZM was able to polarize macrophages over to
an alternative-like phenotype in vitro, as marked by an increase of arginase and
mannose receptor.[112] Here we show that AZM-polarized cells also have the ability to
function in the same manner as AAM by participating in stimulating the production of
fibrotic proteins. Our hypothesis of how this occurs is depicted in Figure 2.13. When
cultured with fibroblasts in vitro, AZM-polarized macrophages increase production and
activation of TGF-β, in addition to increasing the production of the AAM effector protein
arginase. These macrophages also appear to cause fibroblasts to increase production
of fibronectin, an effect which appears to be dependent on the drug’s impact upon TGFβ. This data is consistent with published reports of AAM in pulmonary repair and
fibrosis, where these cells are correlated with increases in arginase, TGF-β, and
fibronectin, with the novelty of the AZM-induction of these effects.[40-43] We have also
demonstrated here a direct dependence of arginase production on TGF-β activation,
which is a novel finding. However, the AZM-polarized cells are also increasing MMP-9
production, a result that was not expected (Figure 2.13). As shown by the TGF-β
neutralization experiments, this is not dependent on TGF-β activation, whereas
increased fibronectin production is. In fact, fibronectin shows a dependence upon TGFβ activity. This is demonstrated both when TGF-β is reduced indirectly, through the
arginase inhibitor BEC, and directly, by a TGF-β neutralizing antibody. Because MMP-9
appears to be independent of these mechanisms, we hypothesized that MMP-9 may be
participating in the activation of TGF-β. When MMP-9 itself is inhibited, the expected
decrease in activated TGF-β did not occur, suggesting an alternate mechanism through
which TGF-β is being activated in this co-culture system. However, fibronectin is also
decreased when the MMP-9 inhibitor is added. This indicates that MMP-9 does have
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some role in the increase in fibronectin caused by AZM treatment. Whether this effect is
direct or indirect is unknown.
As discussed in Chapter 1, TGF-β signaling causes upregulation of fibrotic
proteins from cells such as fibroblasts.[40, 130] Conversely, MMP-9 is able to degrade
the same products to cause ECM turnover.[77, 85] Here, we show that AZM is causing
both activation of TGF-β and increased production of MMP-9. Therefore, it is possible
that AZM has caused a form of its own negative-feedback; in that MMP-9 is available to
degrade excess fibrotic proteins produced by TGF-β signaling. While fibronectin
concentrations are increased in the system, collagen concentrations are not, lending
support to this theory. Furthermore, if increases in both TGF-β and MMP-9 lead to a
homeostasis in the lung, rather than a shift to either fibrosis accumulation or excess
damage, this may explain why patients with CF do well on AZM.[50, 102, 104]
Another surprising result from these experiments is that AZM does not appear to
cause an increase in production of collagen I or III from the co-culture. Collagen I and III
are two forms of collagen that are upregulated and secreted by epithelial cells,
macrophages, and fibroblasts in response to pulmonary injury, and are often associated
with fibrin and fibronectin in the phases of ECM remodeling.[56] Therefore, these
collagens were expected to be affected in the same manner as fibronectin, which was
found to be untrue. Indeed, collagen III is even increased, as measured by western blot,
when the TGF-β neutralizing antibody is added to the cells treated with AZM. While the
results regarding collagen were unexpected, this molecule will be of further study in
Chapter 3.
The last conclusions to be made from these data concern the potential
mechanism of AZM. We previously demonstrated that AZM increased IKK-β expression
early after drug exposure (10min), while decreasing NF-κB expression at that same time.
These results are interesting, because typically an increase of IKK-β is accompanied by
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an increase in NF-κB activation, while AZM is causing changes in the activation of these
molecules in opposing directions. It has been shown, by Fong, et al, that IKKβ can
inhibit activation of the classical macrophage, by crosstalk through Stat1 pathway. [113]
The Stat1 pathway provides signaling from IFN-γ to induce the markers of CAM, such as
iNOS. Therefore, we hypothesized that AZM may be increasing IKKβ, which is inhibiting
the activation of the CAM in order to allow the alternative-like phenotype to take its
place. We are currently evaluating the effect of AZM upon Stat-1 phosphorylation in our
in vitro experiments.
We have previously demonstrated that inhibiting IKK-β with IKK16 caused a
reversal of the effect AZM on arginase activity in the macrophages. However, these
data show that IKK16 not only reverses AZM’s effect on arginase activity in
macrophages, but also in fibroblasts alone and co-cultured with macrophages. Further,
IKK16 reverses AZM’s effect on TGF-β activation, as well as increases in MMP-9 and
fibronectin concentrations. This indicates that IKK-β may play a role in AZM-induced
macrophage polarization and the resultant increase in fibrotic mediators (Figure 2.13).
The data generated in these experiments become important for further analyses.
If patients with CF have an increase in this type of macrophage when they are treated
with AZM, they might also have increases in the pro-fibrotic protein production which
could increase pathologic progression. Alternatively, the suppression of the CAM
phenotype may prevent some of the hyperinflammation inherent in the disease, which
may be beneficial. However, it is unknown how these pro-fibrotic changes may develop
in the presence of multiple other cell types. Therefore, the next chapter will study AZM
treatment in the setting of P. aeruginosa infection in vivo.
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Figure 2.13. Hypothetical schematic of the production of the fibrotic mediators from
macrophages co-cultured with fibroblasts with and without treatment with AZM.

Copyright © Susan Elizabeth Birket 2012
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Chapter 3: Azithromycin alters fibrotic response to P. aeruginosa infection
A. Introduction
While the experiments outlined in Chapter 2 established that AZM-polarized
macrophages can affect fibroblasts and cause increases in production of fibrotic
mediators, it is also important to understand how AZM-polarized macrophages influence
other components of the immune system in response to infection with P. aeruginosa. In
order to examine the effects on macrophage phenotype, fibrotic mediators, and
pulmonary damage, a murine infection model was utilized.
Previous experiments with the murine model demonstrated that AZM has similar
effects on the macrophages in vivo as it did in vitro. When C57Bl/6 mice were pretreated with methylcellulose vehicle or AZM and infected with P. aeruginosa, the AZM
group had higher survival rates, compared to control treated mice, although body weight
and bacterial burden were not significantly different.[114] In these experiments,
macrophages were also found to show higher surface expression of mannose receptor
and lower surface expression of CD80 in AZM treated mice 7 days after infection,
indicating a shift toward the alternative phenotype. This was confirmed with increased
arginase activity at the same timepoint in AZM treated mice. Lastly, histological
examination determined that treatment with AZM shifted the infiltrating cellular response
to infection from neutrophilic (in the control mice) to monocytic. This is significant,
because, as mentioned previously, CF is a neutrophilic-mediated inflammatory disease.
Furthermore, the switch to a monocytic response was concurrent with peak bacterial
burdens.[114]
Previous work in our lab established infection models with this bacterium in
multiple strains of mice. In experiments to determine the proper infectious dose of
bacteria, mice were infected with CFUs ranging from 105 to 1010. C57Bl/6 mice bias
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toward a Th-1 cytokine response to infection and are generally more susceptible to the
generation of fibrosis. [131] These mice responded to infection with P. aeruginosa with
a 50% lethal dose (LD50) of about 106 CFUs. In contrast, BALB/c mice have a bias
toward producing Th-2 cytokines in response to infection and are typically more resistant
to fibrosis development. [131] Likewise, they were also more resistant to the P.
aeruginosa infections. All of the BALB/c mice infected with CFUs up to 109 survived, yet
all mice infected with CFUs of 1010 succumbed, showing a more resistant phenotype, as
reflected by the high LD50. The third strain of mouse used was chosen as part of our
investigations into AZM mechanism; the IL-4rα-/- mouse strain. This genetic knockout
mouse lacks part of the IL-4 receptor in immune cells, and is unable to respond to either
IL-4 or IL-13, as both cytokine receptors require the IL-4rα domain to function. This
strain was bred onto a BALB/c background, however the IL-4rα-\- mice responded to
infection with P. aeruginosa much more similarly to the C57Bl/6 – with an LD50 in the
range of 106. These mice also lose the resistance to fibrosis that the BALB/c strain
demonstrates, suggesting that IL-4 and IL-13 signaling, perhaps through the AAM, plays
a role in preventing fibrosis development. This suggests that activity of alternative
macrophage activation is protective upon challenge with this extracellular pathogen.
Because of the phenotypic similarities of the IL-4αr-/- strain when infected, C57Bl/6 mice
were used as the control mice for the knockout strain in the experiments described here.
Addition of AZM to the co-culture increased production of the pro-fibrotic proteins
arginase, TGF-β, and fibronectin (Chapter 2). Additionally, production of the protease
MMP-9 was increased by AZM as well. These data show that AZM is capable of
polarizing to an alternative-like, pro-fibrotic phenotype. The increase in MMP-9 levels,
however, identifies this phenotype as distinct from the traditional AAM phenotype, and
may be one reason that AZM has a positive effect on patient outcomes. Previous work
has also established that AZM is capable of polarizing the macrophage to the alternative
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phenotype in vivo. However, the impact that the AZM-polarized macrophage exerts
upon the resulting fibrotic process in the mouse model has yet to be determined.
Because of the increased concentrations of arginase, TGF-β, MMP-9, and fibronectin
found in vitro, the same markers were evaluated in mice. To replicate chronic therapy in
the CF patient, mice were pre-treated with AZM, and treatment was continued
throughout the course of the infection, so that the AZM-polarized macrophages should
persist. The aim of this chapter is to determine how the AZM-polarized macrophages
affect fibrosis in a pulmonary model of infection. We hypothesize that AZM-induced
alternative macrophage polarization in mice infected with P. aeruginosa promotes
fibrosis development in the lungs.

B. Methods
Mice
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
BALB/c-Il4ratm1Sz/J strain, homozygous for the Il4ratCAMSz targeted mutation, was bred
in-house. IL4rα is a common chain shared by IL4r and IL13r, and is required for
transmitting signal from both cytokines.[132, 133] All animal studies were approved by
the University of Kentucky Institutional Animal Care and Use Committee. Mice were
housed under conditions of pathogen free isolation and were transferred to a biosafety
level 2 housing unit after infection, at which time all mice were within 5 to 7 weeks of
age.

Azithromycin Dosing
Tablets of AZM (Pliva Inc., Zagreb, Croatia) were triturated and the powder was
suspended in 2% methylcellulose. Beginning 4 days before infection, mice were given
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AZM at 0.16 g/kg of body weight in 150 μl or vehicle only via oral gavage in order to
reach a steady-state concentration of drug exposure at the time of infection.[114] AZM
and vehicle administration was continued once daily until the time that the mice were
killed. Groups of three to six mice per time point per group were used.

Intratracheal Infection
The clinically derived mucoid strain P. aeruginosa M57-15 was utilized in these
experiments. The bacteria were grown in Trypticase soy broth (TSB) to mid to late log
phase before being incorporated into agarose beads.[134, 135] Utilizing growth curve
information and the optical density of the culture, we established the appropriate starting
number of bacteria required to produce a bead preparation that would result in an
inoculum that fell within the desired range at the time of infection.[114] Bacteria were
mixed with agarose at a temperature of 55°C. That mixture was then added to rapidly
stirring and frothing mineral oil at a temperature of 50°C. The mineral
oil/bacterial/agarose mixture was rapidly cooled by adding ice to create formation of
bacteria-filled agarose beads. Beads were washed with PBS and allowed to settle for
retrieval of beads in the range of 10-100μm. The beads were immediately
homogenized, and the number of CFU was determined after overnight growth on
Trypticase soy agar. The P. aeruginosa laden agarose beads were then diluted to
achieve the desired inoculum for each strain infected. The beads were instilled
intratracheally by using a blunted 24-gauge curved inoculation needle while the animals
were under isoflurane anesthesia. To confirm that the mice received the desired
inoculum, an aliquot of the bead preparation used was homogenized and plated on
Pseudomonas selection agar immediately after infection and the numbers of CFU were
counted after overnight incubation.
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Tissue Harvest
The mice were humanely euthanized on day 0 and on post-infection days 3, 7,
and 14. Bronchoalveolar lavage was performed to obtain a representative sample of the
airway compartment. The lungs were lavaged with 5 ml of buffered solution containing
0.3 mM EDTA in 1-ml aliquots. The first 1 mL, called “first wash,” was collected
separately and centrifuged, and the supernatant was saved and frozen at -80°C for
cytokine measurements. Pelleted cells from the first washes were added back to the
remainder of each lavage fluid sample. The lungs were removed, with lobes saved for
histological analysis. The remainder was digested in RPMI medium containing 5% heatinactivated fetal calf serum with 1 mg/mL collagenase A and 50 U/mL DNase for 1 h at
37°C. The lung fragments were then pushed through 70 μm mesh screens to create a
single cell suspension, and the red blood cells were lysed in a hypotonic solution. These
preparations were analyzed as the lung interstitium. An aliquot was plated to assess the
bacterial burden by manual counting of the numbers of CFU on Pseudomonas selection
agar. Pseudomonas specific agar was utilized to avoid contamination from the upper
airway flora. A second aliquot was saved in RIPA buffer for later protein analysis.

Adoptive Transfer
Bone marrow-derived monocytes and splenic T cells from BALB/c mice were
purified using negative selection, with magnetic beads (Stem Cell Technologies,
Vancouver, BC, Canada). Cell numbers transferred and timing of transfer were chosen
based on preliminary experiments. Mice were anesthetized and 1 x 106 T cells or 1 x
106 T cells plus 1 x 106 monocytes were injected retro-orbitally one day before infection.
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Flow cytometry
Surface protein expression and intracellular cytokine secretion were
characterized by flow cytometry. Lavage and digest cell aliquots were incubated with
combination panels of fluorescently labeled antibodies (Abs) for CD11b, CD11c, GR1,
and CD4. The cells were washed thoroughly and resuspended in phosphate-buffered
saline for analysis. The labeled cells were analyzed with an LSRII flow cytometer
system (BD Biosciences), and 50,000 events were routinely acquired per sample. In
figures in which cell numbers are given, the percentage of the gated cell subset was
multiplied by the number of cells manually counted in each sample. FlowJo software
(Tree Star, Ashland, OR) was used to analyze the data.

ELISA assay
Cell culture supernatants were analyzed and the MMP-9 and fibronectin
concentrations quantified by indirect ELISA. Samples were diluted in coating buffer and
incubated at 4°C overnight for adherence to the ELISA plate. Wells were blocked, then
incubated with an antibody specific to MMP-9 (Abcam, Cambridge, MA, USA) and
fibronectin (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), followed by an antirabbit HRP conjugated secondary antibody (Millipore, CA, USA). Wells were analyzed
by OD reading at 450nm, using OptEIA detection reagents (BD, CA, USA). Readings
were compared to a standard curve using MMP-9 or fibronectin recombinant protein.

Histopathology
The mouse lung tissue was excised and immediately fixed in 10% buffered
formalin. After an overnight incubation at 4°C, sections were washed three times with
0.1 M phosphate buffer and were then transferred into 2 ml sterile 20% sucrose (pH 7.2)
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and stored at 4°C. The samples were then transferred into optimal cutting temperature
(OCT) embedding media and incubated at 4°C for 24 h. The fixed cryoprotected tissues
were sectioned at a thickness of 10μm (Thermo Fisher Scientific cryostat) and mounted
on slides to dry overnight. The slides were stained with hematoxylin-eosin (H&E), Van
Gieson TriChrome, or immunohistochemistry, by standardized protocols, and
photographs were taken with an AxioCam HRc camera mounted on a Zeiss Imager.Z1
microscope.

Immunohistochemistry
Slides were washed with PBS+0.02% TritonX-100 (PB:X) for 10 minutes to wash
OCT mounting media. When media washed off, slides were blocked with 5% normal
goat serum (NGS) + 5% bovine serum albumin (BSA) in PBS+0.02% TritonX-100 for at
least 1 hour at room temperature. Primary antibody was added in 1% NGS & 1% BSA in
PB:X overnight at 4◦C, then washed off with PB:X. Secondary antibody was added in
0.5% NGS & 0.5% BSA in PB:X at a 1:160 dilution for 1 hour at room temperature, and
subsequently washed off. Slides were mounted with 20% glycerol and taken to the
microscope within one hour. Pictures were obtained using an AxioCam HRc camera
mounted on a Zeiss Imager.Z1 microscope. Primary antibodies used were specific for
MMP-9 (Abcam, Cambridge, MA, USA), fibronectin (Santa Cruz Biotechnology, Inc,
Santa Cruz, CA, USA), arginase-1 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA,
USA), and iNOS (Cayman Chemical, Ann Arbor, MI, USA). Secondary antibodies used
were goat-anti rabbit IgG-FITC (Sigma Aldrich, St. Louis, MO, USA ), and goat-anti
rabbit IgG-Texas Red (Abcam, Cambridge, MA, USA). Intensity of staining was
quantified using the program ImageJ (National Institutes of Health). All images for each
mouse were averaged, and the median fluorescence intensity is represented graphically.
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TriChrome
Slides were stained with Weigert’s hemotoxylin for 3 minutes, washed, and followed
by Van Gieson’s solution staining, consisting of 0.05% acid fuschin in saturated aqueous
picric acid. Slides were then dried with ethanol and cleared with xylenes to remove
excess dye. Twenty-four hours after being coverslipped, images were obtained as
described above.

Pathology Scoring
All slides were assessed for severity of four markers of lung damage;
peribronchiolitis, bronchitis, alveolitis, and interstitial pneumonitis. Peribronchiolitis is
identified as inflammatory cells surrounding a bronchiole; bronchitis occurs when the
inflammatory cells are within the epithelium of the bronchial epithelium; alveolitis is the
presence of inflammation within the alveolar spaces; and interstitial pneumonitis is
defined as increased thickness of the alveolar walls, due to inflammatory cells or
accumulation of fluid. Damage was scored on a scale of 0 to 4, with 4 being the
maximum inflammation and 0 being no inflammation.[136] Scores were averaged for
each marker, and graphed for statistical analysis in GraphPad Prizm (GraphPad
Software, La Jolla, CA, USA).

Statistical Analysis
Results are reported as mean ± SD, except where indicated, and compared using
GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Data were compared via
one- or two-way ANOVA where appropriate, followed by Bonferroni’s post-test for
individual comparisons. Differences were deemed statistically significant at a p value
<0.05.
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C. Results
AZM alters macrophage infiltration
C57Bl/6 mice were dosed with AZM and then infected with P. aeruginosa to
analyze the infiltration of immune cells into both the lung and the airway spaces. Cells
were analyzed by flow cytometry for markers identifying infiltrating macrophages
(CD11b+), resident alveolar macrophages (CD11c+), neutrophils (CD11b- GR1+), and T
cells (CD4+). Importantly, macrophage numbers were increased at day 7 in the lavage
samples in mice treated with AZM compared to controls, and the neutrophils in the lung
digest had a corresponding decrease in the AZM group (Figure3.1a, b). CD11c+ was
used to identify resident alveolar macrophages, although this marker is also on dendritic
cells[137]; these cells were unchanged in either the lung digest or in the lung lavage.
CD4+ T cell numbers were increased at day 7 in the lung lavage as well as
macrophages in mice who received AZM. This is followed by an increase in T cells at
day 14 in the lung digest in the same group of mice. Therefore, in addition to previous
data showing that AZM is altering the phenotype of the macrophages in vivo to the AAM
[138], the drug is also increasing the presence of the infiltrating macrophages and T cells
as infection is beginning to resolve.
However, in the IL-4rα-/- mice, AZM had different effects on cellular infiltration.
Total cell numbers were decreased in mice that received AZM at day 3 compared to the
control group. At the same timepoint, infiltrating macrophages, identified as CD11b+
cells, were decreased in both lung digest and lavage (Figure3.1c, d). There were no
differences between the treatment groups in any of the other cell types, including
neutrophils. It is important to remember that the T cells in these mice are also affected
by the IL-4rα-/- mutation, and this may be why there were no differences between the
groups. Nevertheless, while the IL-4rα-/- mice do not maintain the neutrophilic response
to infection, the mice still show increased monocytic infiltrates with AZM treatment.
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Figure 3.1. Immune cell infiltration in to the lungs. C57Bl/6 or IL4rα-/- mice, 4 per
timepoint per treatment group, were infected with agarose beads containing 1 x 105 CFU
of P. aeruginosa intratracheally and dosed with either AZM or methylcellulose vehicle.
Immune cells were analyzed by flow cytometry in lung digest (a) and lung lavage (b)
samples of C57Bl/6 mice and digest (c) and lavage (d) samples of IL-4rα-/- mice. Data is
representative of 3 replicated experiments. Mean ± SD are reported, with p < 0.05 for the
timepoint (*) and overall between groups (†).
© Copyright 2010, American Society for Microbiology. All rights reserved.
Arginase and iNOS Expression
In order to determine the impact of AZM treatment upon kinetics of AAM and
CAM in the lungs infected with P. aeruginosa, and to address whether the drug elicits
the same effect in the absence of IL-4 and IL-13 signaling, sections from lungs were
stained by immunohistochemistry for arginase (FITC) and iNOS (Texas-Red). The
intensities of the slides were measured by ImageJ (NIH), and median fluorescence
intensity is represented graphically for each group. Representative slides are shown in
panels Figure 3.2a and Figure 3.2d. WT mice showed increased expression of arginase
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at day 3 in the AZM treatment group compared to control (p < 0.0001, Figure 3.2b), and
a decrease of iNOS expression in the AZM treatment group compared to control at days
0 and 3 (p < 0.01, Figure3.2c). This indicated a reduction of the inflammatory effector
protein both four days after AZM treatment began (day 0) and at peak of infection (at day
3). In contrast, IL4rα-/- mice had no differences in arginase expression in the AZM
treatment group compared to vehicle control at any day post-infection (Figure 3.3b).
IL4rα-/- mice treated with AZM had similar iNOS expression kinetics compared to vehicle
control, until day 14 - at which point iNOS remained upregulated in the controls, and was
downregulated in the treatment group (p < 0.01, Figure 3.3c). Overlays of day 14 are
represented in Figure 3.4, which show co-staining and some co-localization of arginase
and iNOS in the control group of the IL4rα-/- mice, but no co-localization in the AZM
treatment group of the same mice.
Lastly, the lack of difference in arginase production in the IL4rα-/- mice suggested
that while baseline levels of arginase were higher than those observed in the C57Bl/6
mice, the production was not changed by either infection or administration of AZM
(Figure3.3c). Upon further analysis, arginase appeared to be produced by cells other
than macrophages. Those sections were stained for both arginase and F4/80, a marker
of macrophages. Indeed, we found that arginase appeared to be more prevalent than
F4/80, especially at day 7, which is represented below (Figure 3.5). This demonstrates
that macrophages are not the only producers of arginase in the lung in our model.
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Figure 3.2. Arginase 1 and iNOS expression in C57Bl/6 mice treated with
methylcellulose vehicle or AZM. Four mice per treatment group per timepoint were
infected with agarose beads containing 1.5 x 105 CFU of bacteria. Lung sections from
mice 0, 3, 7, and 14 days post infection were stained with primary antibodies to both
arginase 1 and iNOS, with either FITC or texas red secondary staining. Representative
slides of at least 3 replicates from C57Bl/6 controls in (a), with mean fluorescence
intensity quantification of arginase (b) and iNOS (c). Samples were run in triplicate.
Significance is indicated for p values < 0.05 (*), < 0.01(**), and < 0.0001(****).
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(a)

Figure 3.3. Arginase 1 and iNOS expression in IL-4rα-/- mice treated with
methylcellulose vehicle or AZM. Four mice per treatment group per timepoint were
infected with agarose beads containing 1.5 x 105 CFU of bacteria. Lung sections from
mice 0, 3, 7, and 14 days post infection were stained with primary antibodies to both
arginase 1 and iNOS, with either FITC or texas red secondary staining. Representative
slides from IL-4rα-/- mice in (d), with mean fluorescence intensity, ± SD, quantification of
arginase (e) and iNOS (f). Localization of arginase and iNOS in IL4rα-/- mice at day 14
(g). Panels represent arginase 1 localization, iNOS localization, and merged data, from
left to right. Samples were run in triplicate. Significance is indicated for p values < 0.05
(*), < 0.01(**), and < 0.0001(****).
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Figure 3.4. Arginase 1 and iNOS co-expression in IL-4rα-/- mice treated with
methylcellulose vehicle or AZM. Four mice per treatment group per timepoint were
infected with agarose beads containing 1.5 x 105 CFU of bacteria. Lung sections from
mice 0, 3, 7, and 14 days post infection were stained with primary antibodies to both
arginase 1 and iNOS, with either FITC or texas red secondary staining. Localization of
arginase and iNOS in IL4rα-/- mice at day 14 (g). Panels represent arginase 1
localization, iNOS localization, and merged data, from left to right. Samples were run in
triplicate. Significance is indicated for p values < 0.05 (*), < 0.01(**), and <
0.0001(****).[124]

Figure 3.5. Arginase 1 and F4/80 expression in IL-4rα-/- mice treated with
methylcellulose vehicle or AZM. Lung sections from mice at day 7 post infection with
agarose beads containing 1.5 x 105 P. aeruginosa. Representative slides of at least 3
replicates from IL-4rα-/- mice lung sections stained with arginase-FITC and F4/80-Texas
Red.
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MMP-9 Expression
Next, we examined the effect of AZM on MMP-9 production in the lungs during
immune response to P. aeruginosa, in order to determine the effect of the drug on
mediators of ECM turnover. First, MMP-9 concentrations were measured in BALF
samples via ELISA. WT mice had increased concentrations of MMP-9 in the BALF at
day 7 in the lung lavage of AZM-treated mice as compared to the control group (p <
0.01, Figure 3.6a). However, by day 14, MMP-9 concentration had decreased compared
to vehicle control. Interestingly, this increase in BALF concentrations follows an
increase in arginase production at day 3. In the IL4rα-/- mice, the differences in MMP-9
concentration between the treatment groups were not statistically significant. The mice
also had higher MMP-9 concentrations at day 0, which then decrease after infection in
both treatment groups. These mice also had significantly higher concentrations of MMP9 in the BALF throughout the duration of the infection.
Next, to determine MMP-9 expression in the lung, immunohistochemistry was
performed on lung sections from both C57Bl/6 and IL-4rα-/- mice, using an antibody
against MMP-9 (FITC). Representative slides from each mouse are shown in Figure3.4,
panels c and e. Intensity of the fluorescence was measured using ImageJ, and median
fluorescence is shown graphically below. In WT mice, AZM decreased the MMP-9
expression in the lung at day 3 compared to control (p < 0.0001), with no statistically
significant differences at the later timepoints (Figure 3.7b). In contrast to the WT
controls, IL4rα-/- mice had similar expression of MMP-9 until day 14, at which point the
AZM treatment group had decreased MMP-9 compared to control (p < 0.01, Figure
3.7d). Furthermore, both treatment groups of C57Bl/6 mice had higher concentrations of
MMP-9 in the lung, even at baseline, than did the IL-4rα-/- mice. Taken together, these
data suggest that the C57Bl/6 mice treated with AZM, as well as the IL-4rα-/- mice of both
treatment groups, are secreting MMP-9 into the airways.
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Figure 3.6. Expression of MMP-9 in the BALF in response to P. aeruginosa infection.
Four mice per treatment group per timepoint were infected with agarose beads
containing 1.5 x 105 CFU of bacteria. MMP-9 concentrations were measure by indirect
ELISA from BALF in C57Bl/6 (a) and IL-4rα-/-. Significance is indicated for p values <
0.01(**) and < 0.0001(****), and 0.05 overall between groups (†).
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(a)

(b)

(c)

(d)

Figure 3.7. Expression of MMP-9 in the lung in response to P. aeruginosa infection.
Four mice per treatment group per timepoint were infected with agarose beads
containing 1.5 x 105 CFU of bacteria (b). Lung sections from mice 0, 3, 7, and 14 days
post infection were stained with primary antibody to MMP-9 and secondary antibody
tagged with FITC. Representative slides from C57Bl/6 controls are shown (c). Median
fluorescence intensity is represented quantitatively (d). Representative slides of at least
3 replicates from IL-4rα-/- mice are shown (e). Median fluorescence intensity, ± SD, is
represented quantitatively in (f). Samples were run in triplicate. Significance is indicated
for p values < 0.01(**) and < 0.0001(****), and 0.05 overall between groups (†).

Fibronectin Expression
Next, we set out to determine the effect of AZM on changes in fibronectin
concentration over time in the response to P. aeruginosa infection, and whether IL-4rα-/74

mice would respond similarly. ELISA was performed on BALF to measure fibronectin
concentration in the alveolar space. WT mice treated with AZM had increase fibronectin
concentration in the BAL at day 7 (p < 0.01) but decreased concentration at day 14 postinfection compared to control mice (p < 0.0001, Figure 3.8a). IL4rα-/- mice had higher
levels of fibronectin at both day 3 and day 7 compared to control mice. Though this
difference was not statistically significant at any given timepoint, the overall difference
has significance over time (Figure 3.8b).
To determine fibronectin expression in the lung, immunohistochemistry was
performed on lung sections from each mouse strain. Representative slides from each
group are shown in Figure3.5, panels c and e. Quantification of median fluorescence
intensity from ImageJ is represented graphically. WT mice treated with AZM had
increased fibronectin expression at day 3 (p = 0.05), but decreased expression at days 7
and 14 (p = 0.05 and p < 0.0001, respectively, Figure 3.9b), compared to vehicle control.
The control group had a decrease in concentration at day 7, but the subsequent
increase at day 14 left the fibronectin concentrations roughly at the level of baseline. In
contrast, the mice that were treated with AZM had significantly lower levels of fibronectin
expression in their lungs at day 14. This may be indicative of reduced fibrotic changes
secondary to lessened damage.
IL4rα-/- mice had no differences in fibronectin expression in the lung at any day
post infection between the treatment groups (Figure 3.9d). However, both groups of
IL4rα-/- mice had an initial decease in fibronectin expression from day 0 to day 7, and
then rebound expression, with day 14 fibronectin production similar to day 0 levels.
There was also much less fibronectin in the lungs of the IL4rα-/- mice compared to
C57Bl/6 controls. Lastly, fibronectin expression corresponds to the pattern of arginase
expression, shown above, especially at days 3 and 7. This data suggests that arginase
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is increasing fibronectin expression in the in vivo model as was also the case in our in
vitro co-culture work (Chapter 2).

Figure 3.8. Expression of fibronectin in BALF in response to P. aeruginosa infection.
Four mice per treatment group per timepoint were infected with agarose beads
containing 1.5 x 105 CFU of bacteria. Fibronectin concentrations were measure by
indirect ELISA from BALF in C57Bl/6 (a) and IL-4rα-/-. Samples were run in triplicate.
Significance is indicated for p values < 0.5 (*), < 0.01(**) and < 0.0001(****) and 0.05
overall between groups (†).
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(c)

(b)

(d)

Figure 3.9. Expression of fibronectin in the lung in response to P. aeruginosa infection.
Four mice per treatment group per timepoint were infected with agarose beads
containing 1.5 x 105 CFU of bacteria. (b). Lung sections from mice 0, 3, 7, and 14 days
post infection were stained with primary antibody to fibronectin and secondary antibody
tagged with FITC. Representative slides from C57Bl/6 controls are shown (c). Mean
fluorescence intensity, ± SD, is represented quantitatively (d). Representative slides of
at least 3 replicates from IL-4rα-/- mice are shown (e). Median fluorescence intensity is
represented quantitatively in (f). Samples were run in triplicate. Significance is indicated
for p values < 0.5 (*), < 0.01(**) and < 0.0001(****) and 0.05 overall between groups (†).
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Collagen Accumulation
Another important fibrotic marker, the ECM protein collagen, was analyzed in our
infection model. Lung lobes from C57Bl/6 and IL4rα-/- mice infected with P. aeruginosa
were sectioned and stained with Van Gieson’s Tri Chrome reagent specific for all
isoforms of collagen. Representative slides for each group are shown in Figure 3.a and
c. Compared to vehicle control, C57Bl/6 mice treated with AZM had less lung damage
early in the infection, but slightly more collagen accumulation around the airways at day
14 post-infection (Figure 3.10a). While AZM treatment was able to prevent much of the
damage associated with the infection, the increased collagen in the treatment group at
day 14 is a significant finding that could represent an overall lack of long-term impact of
AZM treatment in terms of limiting lung damage. In the IL4rα-/- mice, all animals had
increased lung damage compared to both treatment groups of C57Bl/6 mice at all
timepoints (Figure 3.10b). However, AZM-treated mice showed decreased damage
compared to their own (IL4rα-/-) vehicle control group at day 14 (Figure 3.10b).
Each slide taken of Van Gieson stained tissue was assessed for lung damage.
Sections were scored for severity of four pathologies; peribronchiolitis, bronchitis,
alveolitis, and interstitial pneumonitis for C57Bl/6 mice (Figure 3.11) and IL4rα-/- mice.
Peribronchiolitis indicates inflammation and cell infiltration surrounding a bronchiole;
bronchitis occurs when the inflammatory cells are within the epithelium of the bronchi;
alveolitis is the presence of inflammation within the alveolar spaces; and interstitial
pneumonitis is defined as increased thickness of the alveolar walls, due to inflammatory
cells or accumulation of fluid. While these pathologies are often localized to specific
areas of the lung, leaving normal or near-normal tissue in between, each slide was given
a score of the average damage throughout the specific section. In the C57Bl/6 mice
treated with AZM, there was increased peribronchiolitis at day 7 post-infection, as well
as significantly less severe bronchitis at day 3 post-infection. This was accompanied by
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decreased alveolitis in the AZM-treated mice at both days 0 and 3, although this marker
was then increased in these mice at day 7 post-infection compared to controls. These
changes indicate that treatment with AZM may alter the type of damage in the lung, as
well as the time post-infection when the damage occurs. In contrast, the IL4rα-/- mice
which were treated with AZM had less severe peribronchiolitis and alveolitis at days 7
and 14 post-infection, accompanied by less severe bronchitis at day 7 post-infection.
Interestingly, interstitial pneumonitis was more severe than in the C57Bl/6 animals, and
was unchanged with AZM treatment. This suggests that IL-4 signaling may have a
protective effect during infection. Further, while AZM may protect against lung damage,
it may also contribute to collagen accumulation.

(a)

(b)

Figure 3.10. Expression of collagen in response to P. aeruginosa infection. Four mice
per treatment group per timepoint were infected with agarose beads containing 1.5 x 105
CFU of bacteria. Lung sections from mice 0, 3, 7, and 14 days post infection were
stained with Van Gieson’s Tri Chrome. Representative slides of at least 3 replicates
from C57Bl/6 controls (a) and IL-4rα-/- mice (c) are shown. Pink color of the Tri Chrome
stains positively for collagen deposition.
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Figure 3.11. Pathology scoring of C57Bl/6 lungs infected with to P. aeruginosa. Four
C57Bl/6 mice per treatment group per timepoint were infected with agarose beads
containing 1.5 x 105 CFU of bacteria. Lung sections from mice 0, 3, 7, and 14 days post
infection were stained with Van Gieson’s Tri Chrome. Slides were scored for markers of
pathology; peribronchiolitis bronchitis, alveolitis, and interstitial pneumonitis. Data is
represented as mean ± SEM. Samples were run in triplicate. Significance is indicated
for p values < 0.5 (*), < 0.01(**), < 0.001(***), and < 0.0001(****), and 0.05 overall
between groups (†).
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Figure 3.12. Pathology scoring of IL-4rα-/- lungs infected with P. aeruginosa. Four IL4rα-/- mice per treatment group per timepoint were infected with agarose beads
containing 1.5 x 105 CFU of bacteria. Lung sections from mice 0, 3, 7, and 14 days post
infection were stained with Van Gieson’s Tri Chrome. Slides were scored for markers of
pathology; peribronchiolitis bronchitis, alveolitis, and interstitial pneumonitis. Data is
represented as mean ± SEM. Samples were run in triplicate. Significance is indicated
for p values < 0.5 (*), < 0.01(**), < 0.001(***), and < 0.0001(****), and 0.05 overall
between groups (†).
Monocyte Rescue
Because the IL-4rα-/- mice had more severe histological damage than the
C57Bl/6 controls, we decided to do an adoptive transfer of normal monocytes to attempt
to correct this pathology in the post-infection timeframe. IL-4rα-/- mice received normal
cells adoptively transferred from BALB/c mice. Mice received either T cells only or
monocytes and T cells. All mice received adoptively transferred T cells, as the IL4rα-/mice lack this receptor domain on T cells as well.

81

Previous data confirms that the experiments were successful, by detecting IL4rα
on CD11b+ cells in the mice that received normal monocytes and T cells, though not on
CD11b+ cells from mice that received normal T cells only. Additionally, mice that
received both monocytes and T cells display a decreased neutrophilic influx compared to
mice that only received adoptively transferred T cells. This data suggested that the
addition of normal monocytes can alter the inflammatory response.
In order to determine if monocyte adoptive transfer would also modulate other
parts of the inflammatory response, lungs were examined histologically. Lung sections
were stained with Van Gieson’s Tri Chrome and scored for four pathological markers;
peribronchiolitis, bronchitis, alveolitis, and interstitial pneumonitis. The group that
received both monocytes and T cells from normal mice had lower scores of alveolitis and
interstitial pneumonitis at day 3 post-infection compared to mice who received only T
cells from normal mice, although the difference was not statistically significant (Figure
3.13). Importantly, day 3 post-infection is at peak of inflammation response.
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Figure 3.13. Scoring of damage in response to P. aeruginosa infection, with adoptive
transfer of normal immune cells into IL-4α-/- mice. Cells were harvested from BALB/c
mice and retro-orbitally injected into the transgenic strain. Four mice per treatment
group per timepoint were then infected with agarose beads containing 1.5 x 105 CFU of
bacteria. Lung sections from mice 0, 3, and 6 days post infection were stained with Van
Gieson’s Tri Chrome. Slides were scored for markers of pathology; peribronchiolitis,
bronchitis, alveolitis, and interstitial pneumonitis. Samples were run in triplicate. Data is
represented as mean ± SEM. Data were not statistically significant.
MMP-9 Deficiency
In light of the in vitro data suggesting that MMP-9 is a molecule of critical
importance to the AZM-polarized macrophage phenotype, a preliminary experiment was
conducted using MMP-9 deficient mice. Mice that are homozygous null for Mmp9 gene,
on a C57B/6 background, were used for these experiments. These mice have normal
development, though may have decreased neutrophilic influx to sites of
inflammation.[139] This strain of mouse was compared to the C57Bl/6 to determine if
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the lack of MMP-9 would result in increased amount of fibrosis after infection with P.
aeruginosa. We hypothesized that the lack of MMP-9 would result in a buildup of ECM,
as the protease would be unavailable to degrade excess collagen and fibronectin.
Previous studies utilizing the strain of MMP-9 deficient mice have primarily investigated
the role of the protease in inflammation, in diseases such as allergic asthma, ventilator
induced lung injury, and bronchopulmonary dysplasia.[140-142] The impact of MMP-9
deficiency on ECM buildup is currently unknown.
For this experiment, the mice were treated with AZM, infected with 1 x 105 CFUs
of P. aeruginosa, and analyzed 14 days post-infection for the amount of fibrotic proteins
in their lungs. The mice lacking MMP-9 tolerated the infection to the same degree as the
C57Bl/6 mice; the weight loss between the groups was not significantly different at any
of the timepoints, overall there was a significant different over time (Figure 3.14). In
addition, none of the mice in either group grew bacteria on culture at day 14. This
suggests that the MMP-9-/- mice did not have impaired inflammatory response significant
enough to cause impaired bacterial clearance or prolonged infection.
When the lungs were sectioned and stained for presence of collagen, there were
some differences noted between the two strains. The C57Bl/6 mice showed collagen
accumulation at both the pre-infection and the post-infection timepoints (Figure 3.15).
This is not surprising, given previous data with this strain. However, the MMP-9-/- mice
had more collagen accumulating to the airways in both the uninfected mice and the mice
at day 14 post-infection (Figure 3.15). This supports the hypothesis that lack of MMP-9
leads to increased accumulation of fibrosis.
However, when lung sections were stained by immunohistochemistry for
fibronectin, there were no differences in expression of this protein between the two
mouse strains. Representative pictures are shown in Figure 3.16a, and analyzed
graphically in Figure 3.16b. This is an interesting finding, in light of the differences in
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collagen accumulation. This data compliments the rest of the data gathered in this
chapter and in Chapter 2 that shows collagen and fibronectin having different outcomes
in response to the various stimuli. However, this preliminary experiment only examined
a limited set of time after infection; a more detailed study is needed in the future to
determine the role of MMP-9 in the response of fibrotic mediators to P. aeruginosa
infection.

Figure 3.14. Lack of MMP-9 affects mouse weights in response to P. aeruginosa
infection. Weight change of mice in each strain as percentage change from baseline
weight. Four mice per group were infected with agarose beads containing 1.5 x 105 CFU
of bacteria. Data is represented as mean ± SD, with four mice per group. Data were
analyzed by two-way ANOVA, and p < 0.05 over time between groups (†).

Figure 3.15. Lack of MMP-9 causes collagen accumulation. Expression of collagen in
response to P. aeruginosa infection. Four mice per group were infected with agarose
beads containing 1.5 x 105 CFU of bacteria. Lung sections from uninfected mice and
mice 14 days post infection were stained with Van Gieson’s Tri Chrome. Representative
slides of at least 3 replicates from C57Bl/6 controls and MMP9-/- mice are shown. Pink
color of the Tri Chrome stains positively for collagen deposition.
85

(a)

(b)
Figure 3.16. Lack of MMP-9 does not increase fibronectin accumulation. Expression of
fibronectin in response to P. aeruginosa infection. Four mice per group were infected
with agarose beads containing 1.5 x 105 CFU of bacteria. Lung sections from uninfected
mice and mice 14 days post infection were stained with fibronectin-FITC by
immunohistochemistry. (a)Representative slides of at least 3 replicates from C57Bl/6
controls and MMP9-/- mice are shown. (b) Mean fluorescence intensity is represented
graphically. Data were analyzed by two-way ANOVA with Bonferroni’s post-test. Data
were not significant.

D. Conclusion
The hypothesis for this section of experiments, that fibrosis development in
response to P. aeruginosa would depend on the alternative macrophage activation,
turned out to be too simplistic for the interactions taking place in the immune response.
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While these data did show that the AZM-polarized macrophage is affecting fibrosis, as
well as influencing the response to infection, the effects appear to be multifaceted.
In C57Bl/6 mice, AZM caused increased numbers of CD11b+ macrophages to
partition to the airway spaces at day 7 post-infection compared to the control group,
while at the same time resulting in decreased numbers of neutrophils. This analysis by
flow cytometry confirms previous analysis in our lab by histological methods.[138] This
result also shows that macrophages are an important cell type in the immune response.
Therefore, the in vitro data demonstrating AZM’s polarizing effects has increased
significance.
Staining for AAM and CAM markers showed that C57Bl/6 mice have significantly
increased levels of arginase at day 3 in the AZM-treated group, with a corresponding
decrease in iNOS. This shift in effector protein expression mimics the changes seen in
the in vitro data, both in Chapter 2 and previously observed.[112] Interestingly, in this
experiment, the AZM-treated group had a decrease in iNOS at day 0. At this timepoint,
the mice had received four days of drug, but were had not yet infected. Furthermore, in
the IL-4rα-/- mice, there was no difference in arginase expression between the vehicle
control and the AZM treatment groups, but there was a significant decrease in iNOS at
day 14 in the AZM-treated mice. This suggests that AZM may have a protective effect
independent of IL-4/13 signaling.
Both MMP-9 and fibronectin concentrations in BALF mimics macrophage
partitioning in C57Bl/6 mice. Importantly, MMP-9 and fibronectin concentrations are
higher in the BALF in AZM-treated C57Bl/6 mice at day 7, which is when bacterial
burden is highest in the course of this infection. The control mice don’t secrete these
proteins into their airways until day 14 post-infection. When lung sections are stained for
these proteins, the relationships appear to be reversed; MMP-9 and fibronectin are both
decreased in the lung at days 7 and 14 in the mice treated with AZM compared to
87

vehicle controls. Although fibronectin is increased at day 3 post-infection in the AZM
treated mice, MMP-9 is always downregulated in these mice compared to vehicle
controls. This could suggest that what is being made of these proteins is being directly
secreted into the airways, at least at day 7, when the mice had received AZM. It is also
important to note that MMP-9 is produced in other cell types in addition to macrophages.
Pretreatment with AZM has been shown to prevent upregulation of MMP-9 in human
airway epithelial cells.[143] Furthermore, fibronectin in the lung tissue may have been
degraded by the presence of P. aeruginosa. Multiple studies have evidence to support
the ability of this bacterium to bind and subsequently degrade fibronectin in order to
establish infection.[144-146] Degradation of fibronectin by P. aeruginosa could be one
reason for a decrease in fibronectin concentrations in the lung tissues over the course of
the experiment.
When these proteins are examined in the IL-4rα-/- mice, there are little differences
in MMP-9, and no differences in fibronectin between the two treatment groups. While,
the knockout mice had higher concentrations of these proteins in the BALF compared to
the control strain, they also produce less of these proteins in the lung tissues, as noted
both in the representative pictures and in the scales of the median fluorescence intensity
graphs. However, compared to the C57Bl/6 mice, the IL-4rα-/- mice had higher MMP-9
and fibronectin concentration in the BALF, yet lower concentrations of these proteins in
the lung. This suggests that the IL-4rα-/- mice secrete these proteins into the airways to a
higher degree than the C57Bl/6 mice.
Another important observation to make about the immunostaining is that the
localization of these proteins is altered when AZM is given. Some of the proteins, such
as arginase, move from the airways to the interstitium with the addition of AZM, and
some, such as MMP-9, move in the opposite direction. While this is not represented
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when the data is analyzed quantitatively, it may be of importance in the overall immune
response to the infection and the subsequent fibrosis that progresses.
Along with reduced fibronectin in the lungs of mice treated with AZM, there was
correspondingly less damage to the pulmonary tissue. This damage is also manifested
by increased cellular infiltrates and fluid accumulation in sections stained with Van
Gieson’s Tri Chrome. Especially at day 3, which is when mice show the most dramatic
weight loss[138], the damage to the vehicle control group is most significant in the
bronchitis and alveolitis scores, which are both influenced by treatment with AZM.
However, it appears that AZM may be shifting the kinetics of these types of damage to
the later timepoints. Also, there is increased collagen accumulation in this group of mice
at the latest timepoint. Because these experiments were unable to assess physiology or
lung function, it is uncertain what effect the collagen had on the mice in this group.
When the IL-4rα-/- mice were assessed for lung damage and collagen
accumulation, we found that even at baseline, before infection, these mice showed
increases in cellular infiltration, peribronchiolitis, and collagen accumulation. Collagen
was reduced in the AZM-treatment group, which had been receiving drug for four days
by day 0. During the course of infection, both treatment groups of this strain developed
more damage in response to infection that did the C57Bl/6. Again, AZM ameliorated the
damage, with reductions in peribronchiolitis, bronchitis, and alveolitis. Interestingly, in
the IL-4rα-/- mice that were treated with AZM, there was little collagen accumulation seen
on histological examination.
Because damage was so severe in the IL-4rα-/- strain, even at baseline, we
hypothesized that the absence of the alternative macrophage could be the reason. In
fact, when adoptively transferred with normal cells, the group of mice that received
normal T cells and normal monocytes had less damage at the peak of infection. While
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these data were not significant, the sample size for the experiment was low and did not
go to a 14 day timepoint, which might have shown even more differences in recovery.
The hypothesis proposed for this set of experiments was partially supported.
Collagen was increased in AZM-treated mice at later timepoints, following an increase in
arginase in these same mice. Interestingly, there was little collagen present at the day 3
timepoints in all experiments analyzed. This may be due to the high bacterial burden at
this time; Pseudomonas elastases, an extracellular enzyme produced by the bacteria,
has been shown to directly degrade collagen.[147] However, the other fibrotic marker
analyzed, fibronectin, was decreased in AZM-treated mice, even after the increase in
arginase. Furthermore, the increase in arginase in the C57Bl/6 mice was also
accompanied by a decrease in damage, suggesting that blunting the inflammatory
response is the main action of the AZM-macrophage, rather than fibrosis increase.
Whether the decrease in fibronectin or the increase in collagen is more physiologically
relevant to the mice remains unanswered.
Administration of AZM in the murine infection model appears to ameliorate some
of the inflammation and damage associated with the bacterial infection, although it may
also increase some of the fibrotic responses as well. In light of these data, it was
important to investigate the mediators studied in Chapters 2 and 3 in human studies.
Therefore, Chapter 4 will focus on the affect of AZM on fibrotic mediators in subjects with
CF.

Copyright © Susan Elizabeth Birket 2012
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Chapter 4: Azithromycin alters correlations between fibrotic mediators and
inflammatory cytokines in sputum from patients with CF
A. Introduction
The final component outlined in this dissertation examines the fibrotic mediators
studied in chapters 2 and 3 in human subjects. For this study, subjects were recruited
from the University of Kentucky pulmonology clinic who were diagnosed with CF. These
subjects were consented or assented, sputum samples were obtained, and clinical data
was collected from medical records. The sputum samples were analyzed for the fibrotic
mediators identified as important from our in vitro and in vivo animal studies, namely
TGF-β, MMP-9, fibronectin, and MMP-2. MMP-2 was added because human studied
have shown that MMP-9 and MMP-2 often have similar actions in disease states in the
lungs. [148-150]
In addition, inflammatory cytokines were also profiled in these patients. IL-8 and
IL-1β were the cytokines that were identified as the most important in these subjects. IL8 is a classic inflammatory cytokine, and is elevated in the CF airway. [151, 152]. IL-1β,
however, has a more complicated role in the CF disease process. IL-1β is traditionally
considered an inflammatory cytokine, as its activity potentiates inflammatory processes
in multiple pulmonary diseases, including CF. [153, 154] In fact, IL-1β can increase IL-8
in CF lung epithelial cells by activating NF-κB. [154] In general, IL-1β is cleaved from its
pro-form downstream of inflammasome activation, usually in response to microbial
infection.[155, 156] Once cleaved, IL-1β is secreted into the airways to coordinate
inflammatory responses in the lung.[157, 158] However, IL-1β also initiates fibrotic
mechanisms in addition to inflammatory processes.[159, 160] Kolb, et al, showed that
intratracheal instillation with exogenous IL-1β resulted in early increases in inflammatory
cytokine production, such as IL-6 and TNF. The increases in inflammatory proteins were
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followed by late increases in TGF-β and hydroxyproline, the precursor to collagen. In
fact, while inflammatory cytokines peaked at day 7 after IL-1β administration,
hydroxyproline was still elevated by day 60 post IL-1β exposure. The delayed presence
of hydroxyproline could indicate a continued production of collagen. IL-1β can also
activate plasminogen activator inhibitor-1 (PAI-1), a conquence of which is the increase
of collagen and lung fibrosis. [125] IL-1β has an additional direct effect on the CF
airway; it can increase the MUC5AC gene, which encodes for mucin – a major
component of mucus.[161] Upregulation of MUC5AC can cause increased
accumulations of mucus in the airways. This effect also appears to be through NF-κB.
Because IL-1β has such wide implications on the CF airway, and on mediators important
for this study, we felt that this would be an important cytokine to include in our analysis.
Our lab has previously examined sputa from CF subjects for markers of
alternative macrophage activation. This study[114] showed that subjects who were
infected with P. aeruginosa had higher levels of mannose receptor and arginase activity
compared to subjects who were uninfected. Arginase was inversely associated with
FEV1, and the correlation was stronger in those subjects infected with P. aeruginosa (r =
-0.662, p = 0.001). These subjects also had statistically significantly higher levels of the
cytokines IL-12 and IL-1β in their sputa. In this previous work, the impact that AZM
treatment had upon macrophage disposition was a secondary objective.
Based on the in vitro and in vivo data showing that AZM treatment causes
increases in fibrotic mediator production, we set out to determine whether this
relationship would be true in the lungs of patients with CF. For the current study, the
focus was to determine whether fibrotic mediators in sputa of patients with CF are
affected by AZM treatment, and whether their expression levels correlated with
alternative macrophage activation. Therefore, we hypothesized that AZM therapy in
patients with CF increases markers of fibrosis buildup and decreases markers of
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ECM turnover in the lungs, and would be correlated with alternative macrophage
activation.

B. Methods
Study design
Subjects were recruited from the adult and pediatric outpatient pulmonology
clinics at the University of Kentucky Medical Center. Inclusion criteria were: diagnosis of
cystic fibrosis, age 2 – 50 years, ability to extemporaneously produce sputum samples,
and currently in a stable state of disease (non-exacerbation) as deemed by the treating
physician. Exclusion criteria were presence of HIV, cancer, history or organ transplant,
pregnancy or breastfeeding, or current IV antibiotic therapy. Subjects were consented if
18 or over and assented with parental consent if under 18. Sputum samples were
collected, and clinical data from the time of the sample was obtained from the subjects
chart. This included medication history, lung function parameters, and bacterial
colonization status at the time of the sample. Subjects were considered positive for a
given organism if that organism was reported to have grown from sputum sample/throat
swab at the time of the sample collection. Microbiological data was obtained by the UK
Medical Center. All processes were approved by the Internal Review Board at the
University of Kentucky Medical Center.

Sample processing
Two to 5 mL of spontaneously expectorated sputum was collected and
immediately placed on ice. Samples were digested in 0.1% diothiothreitol and DNase at
30 μg/mL in phosphate buffer for 30 min, with agitation. Supernatants were frozen at 80°C, while cells were washed, counted, and frozen in RNAlater (Applied Biosystems,
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Foster City, CA, USA) for subsequent gene analysis. Because of the variability
generated by this processing, analyses that follow were all normalized to either total
protein or cell counts in each sample. This allows for normalization to volume of sample
collected.

TGF-β Activity
Sputum supernatants were quantified by ELISA using the TGF-β1 Emax
ImmunoAssay System (Promega, Madison, WI, USA). Samples were diluted in PBS
and processed with an acid wash per manufacturer’s instructions. Plates were coated
with a mAB specific for TGF-β, and samples were added to the wells along with a
standard curve prepared using supplied TGF-β1 standard. Polyclonal anti-TGF-β1
antibodies were applied, followed by washing and incubation with horseradish
peroxidase conjugate. Development solution was applied to the samples, and the OD
readings were obtained at 450 nm and compared to the TGF-β1 standard curve. TGF-β
concentrations were normalized to cell count. Because the DTT processing of the
sputum sample interfered with the assay, all the samples were acid washed, and thus
represent total concentration of TGF-β. However, the TGF-β that is expectorated with
the sputum is likely endogenously activated, as latent TGF-β is still bound to the matrix.

ELISA assay
Sputum supernatants were isolated and the MMP-9, fibronectin, and MMP-2
concentrations quantified by indirect ELISA. Samples were diluted in coating buffer and
incubated at 4°C overnight for adherence to the ELISA plate. Wells were blocked, then
incubated with an antibody specific to MMP-9 (Abcam, Cambridge, MA, USA),
fibronectin(Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), or MMP-2(Abcam,
Cambridge, MA, USA) followed by an anti-rabbit HRP conjugated secondary antibody
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(Millipore, CA, USA). Wells were analyzed by OD reading at 450nm, using OptEIA
detection reagents (BD, CA, USA). Readings were compared to a standard curve using
MMP-9, MMP-2, or fibronectin recombinant protein, and values were normalized to cell
count.

Cytometric bead array
The levels of the following cytokines were measured in the sputum supernatant
samples by using cytometric bead array assay kits (BD Biosciences): IL-8, IL-1β, IL12p70, TNF-α, IL-10, and IL-6. Bead populations of distinct sizes that were coated with
capture antibodies specific for each cytokine were incubated with a 5-fold dilution and a
50-fold dilution of each sample for 3 h at room temperature along with a phycoerythrinconjugated detection antibody. The beads were then washed, and the fluorescence
intensity was assayed by flow cytometry, as outlined above. Intensities were then
compared to those on a standard curve generated for each cytokine to determine the
concentration in each sample.

Statistical Analysis
Results are reported as mean ± SD and analyzed using GraphPad Prism (GraphPad
Software, La Jolla, CA, USA). Data were compared via ANOVA, followed by
Bonferroni’s post-test for individual comparisons, or unpaired student’s t-test.
Correlations were analyzed by linear regression. Nominal data was analyzed by
Fischer’s exact test. Principal component analysis (PCA) was performed as a method of
data reduction to analyze multifactorial variability. PCA was run using Statview (Nesbit,
MS, USA). Comparisons between PCA groups were done using Mann-Whitney Rank
test. Differences for all statistics were deemed statistically significant at a p value <0.05.

95

C. Results
Subject Demographics
Thirty subjects were recruited for the study, with 66 samples collected from
September 2009 until December 2010. For 37 of those samples, supernatants were
saved and protein analysis was available. The subject demographics are reported in
Table 4.1. Approximately 69% of the subjects were being treated with AZM. This was to
be expected, as use of AZM is now wide-spread among CF treating physicians,
especially for patients who are colonized with P. aeruginosa.[92] Although only 49%
percent of the subjects were colonized with P. aeruginosa, nearly 80% of subjects were
positive for S. aureus. This is not surprising, given that the majority of subjects were
under 18, and younger than the typical age at which the incidence in P. aeruginosa
colonization rises. This is an age when S. aureus infections are more prevalent.[5]
Lastly, 62% of subjects were homozygous for the ΔF508 mutation. The remaining
subjects had one ΔF508 allele and second mutation on their other allele.
Table 4.2 compares the demographics of the study population between subjects
with and without AZM treatment, and between subjects with and without P. aeruginosa
colonization. Of those subjects being treated with AZM, 73% were pediatric, while all of
the subjects not being treated with AZM were pediatric. Additionally, only 56% of
subjects positive for P. aeruginosa, while 95% of those subjects negative for P.
aeruginosa were pediatric. Lung function was measured in these subjects as FEV1 and
forced vital capacity (FVC) % predicted. While FEV1 is the most common method of
tracking patients’ lung function, FVC, which measures the total volume of air expired,
also indicates lung compliance and function. Both lung function measurements, FEV1
and FVC % predicted, were significantly higher in the subjects who were not being
treated with AZM. Lung function measurements were also significantly higher in the
subjects who were not colonized with P. aeruginosa than those who were. Interestingly,
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there was no significant difference between those subjects who were either treated with
AZM or not who were colonized with S. aureus. There was also no significant
differences between those positive and negative for P. aeruginosa who colonized with S.
aureus.
The lung function measurement ranges for FEV1 and FVC % predicted were
quite broad, although the age range was not. This suggests that we achieved our goal
of including patients at all stages of disease. While FEV1 decline in patients with acute
exacerbation indicates an increase in inflammation, FEV1 decrease in stable patients
(such as our subjects) indicates and increase in amount of fibrosis accumulation, and
therefore a change in lung architecture. In these subjects, when FEV1 % predicted is
regressed against age, the lowest FEV1 values occur over five decades of age (Figure
4.1a). Despite this, there was a strong negative correlation of lung function and age.
When compared by pediatric vs. adult subjects, FEV1 % predicted values were
significantly higher in pediatric patients (Figure 4.1b). Similarly, FEV1 % predicted was
higher in patients not taking AZM – most likely because these patients had less severe
disease overall (Figure 4.1c).
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Table 4.1. Demographics of subjects enrolled in the study.

Table 4.2 Demographics analyzed by AZM treatment and P. aeruginosa colonization
status.
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Figure 4.1. FEV1 % predicted of subjects enrolled in the study. (a) FEV1 % predicted
compared by linear correlation to age of subjects. Statistical analysis was performed
using linear regression. (b) FEV1 % predicted compared by pediatric, < 18 years of age,
or adult subjects, ≥ 18 years of age. Data was analyzed by student’s t-test. (c) FEV1 %
predicted compared by AZM treatment. Data was analyzed by student’s t-test.
Statistical significance indicated on the graphs.
Fibrotic markers and AZM
Concentrations of TGF-β, MMP-9, and fibronectin protein were measured in
sputum samples collected from these subjects. MMP-2 concentration was also
assessed to determine if the activity of this protease was similar to MMP-9 in this subject
population. When protein concentrations were compared between subjects who were
receiving AZM and those who were not, TGFβ- was the only fibrotic marker that was
differed statistically. Interestingly, subjects on AZM had decreased levels of TGF-β in
their sputum (Figure 4.2, p = 0.02). Concentrations of MMP-9 and MMP-2 had nearly
identical means between the two groups (Figure 4.2b and d, p = 0.65 and 0.98
respectively), suggesting that treatment with AZM does not affect these markers.
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Fibronectin trended toward a higher mean value in the group of subjects receiving AZM
than those not receiving AZM, though it the difference was not statistically significant
(Figure 4.2c, p = 0.10). Although this is only a trend toward higher concentrations in
subjects receiving AZM, it is possible that more samples would detect a greater
difference between the two groups.

Figure 4.2. Fibrotic mediators from CF subjects’ sputa. Subjects were analyzed with
regard to their AZM treatment status. TGF-β (a) was measured by TGF-β1 Emax
ImmunoAssay System, while MMP-9 (b), fibronectin (c), and MMP-2 (d) were measured
by indirect ELISA. to the subjects’ dose (mg) of AZM. Data were analyzed by student’s
t-test and considered significant at p < 0.05.
Fibrotic markers and Pseudomonas
Because AZM has traditionally been used in patients with CF when they become
colonized with P. aeruginosa,[50, 103] colonization status for this organism was
determined at the time of the sample collection. The same proteins, TGF-β, MMP-9,
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fibronectin, and MMP-2, were analyzed with regard to subjects’ infection status.
Interestingly, subjects that were positive for P. aeruginosa had decreased concentrations
of TGF-β in their sputa compared to subjects whose cultures were negative (Figure 4.3a,
p = 0.03). MMP-9 and fibronectin concentrations had very little difference in mean
between the group positive for P. aeruginosa and the group that was not (Figure 4.3b
and c, p = 0.53 and 0.44, respectively), indicating that the presence of this pathogen did
not affect these two proteins. MMP-2 showed a trend toward increased concentrations in
subjects with positive cultures, though the difference was not statistically significant
(Figure 4.3d, p = 0.09).
In an effort to determine if AZM or PA status was more influential on fibrotic
marker concentration, especially in the case of TGF-β, subjects on AZM who were
positive for P. aeruginosa were compared to those who had negative cultures. Subjects
not treated with AZM and negative for P. aeruginosa were also included. There were no
subjects who were positive for P. aeruginosa but not treated with AZM. Because the
subjects were recruited without prior knowledge of their AZM treatment status or their
microbiological culture results, the lack of an AZM-PA+ subject cohort is indicative of
prescribing practices at the our clinic sites. There were no statistical significances
between the groups receiving and not receiving AZM. However, there was a significant
difference in TGF-β concentrations between the AZM+PA+ subjects and the AZM-PAsubjects (Figure 4.3e, p< 0.05). There was no significant difference in MMP-9, MMP-2,
or fibronectin concentrations between these groups of subjects (Figure 4.3 f, g, h). This
data suggests that AZM may be more influential to TGF-β concentrations than the
presence of P. aeruginosa.

101

Figure 4.3. Fibrotic mediators from CF subjects’ sputa and P. aeruginosa. Subjects
were analyzed with regard to colonization status of P. aeruginosa (PA). TGF-β (a) was
measured by TGF-β1 Emax ImmunoAssay System, while MMP-9 (b), fibronectin (c), and
MMP-2 (d) were measured by indirect ELISA. to the subjects’ dose (mg) of AZM. Data
in graphs a-d were analyzed by student’s t-test and considered significant at p < 0.05.
Data in graphs e-h were analyzed via student’s t-test for group AZM+PA+ vs group
AZM+PA- and via ANOVA with Bonferroni’s post-test for all data. Data were considered
significant at p < 0.05.
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Fibrotic Markers and Staphylcoccus
Because such a higher percentage of subjects grew positive cultures for S.
aureus, it was important to determine if the presence of this pathogen was influencing
the concentration of these proteins in the subjects’ sputa. This is particularly important
considering that most patients are of the age in which S. aureus is a prevalent infection,
and because of the emerging nature of this pathogen in this population. However, when
the subjects were grouped on the basis of presence or absence of a positive Staph
culture, there were no statistically significant differences in concentrations of TGF-β (p =
0.20), MMP-9 (p = 0.92), fibronectin (p = 0.72), or MMP-2 (p = 0.98, Figure 4.4). This
suggests that S. aureus is not influencing the concentration of these proteins in this
subject population.

Figureure 4.4. Fibrotic mediators from CF subjects’ sputa and S. aureus. Subjects
were analyzed with regard to infection with S. aureus (Staph). TGF-β (a) was measured
by TGF-β1 Emax ImmunoAssay System, while MMP-9 (b), fibronectin (c), and MMP-2 (d)
were measured by indirect ELISA. to the subjects’ dose (mg) of AZM. Data were
analyzed by student’s t-test and considered significant at p < 0.05.
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Inflammatory Cytokines
Next, inflammatory cytokines were analyzed in the subjects’ sputa. A cytometric
bead array was executed for a group of pro- and anti-inflammatory cytokines. The
cytokines TNF, IL-10, IL-6, and IL-12p70 were measured at below the limit of detection
in all or nearly all the sputa samples. This is interesting, although not entirely
unexpected, as subjects were recruited specifically when in a stable disease state.
Therefore, they would not be expected to be expressing copious amounts of these
inflammatory cytokines in extemporaneously expectorated sputum. However, the
cytokines IL-8 and IL-1β were detectable in all the samples assessed. When compared
between subjects receiving and not receiving AZM, there were no differences in cytokine
concentrations between the subject groups (Figure 4.5a, b, p = 0.22 for both). When
cytokine concentrations were compared with regard to infection status, P. aeruginosa
colonization made no difference to concentration of either IL-8 or IL-1β (Figure 4.5c, d p
= 0.13 and 0.61, respectively). However, subjects with positive S. aureus cultures had
significantly lower concentrations of IL-1β (Figure 4.5e, p = 0.04) compared to those
subjects who were negative for S. aureus. Levels of IL-8 were no different between
subjects positive and negative for S. aureus (Figure 4.5f, p = 0.82).
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Figure 4.5. Inflammatory cytokines from CF subjects’ sputa. IL-8 and IL-1β were
measured by cytometric bead array. Data was analyzed with regard to subjects AZM
treatment status (a) and (b), colonization with P. aeruginosa (PA) (c) and (d), and
infection with S. aureus (Staph) (c) and (d). Data were analyzed by student’s t-test and
considered significant at p < 0.05.
Correlation between lung function, fibrotic, and inflammatory markers
We then examined the correlations between protein concentration and disease
severity. We also examined the correlation of fibrotic proteins among themselves and
with the inflammatory cytokines that were detected in the sputum samples. These
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analyses were important to investigate the relationship between markers of fibrosis and
inflammation. We hypothesized that the markers of fibrosis would be positively
correlated to each other, indicating a fibrotic environment in those subjects being treated
with AZM. We also expected to find that inflammatory cytokines would have inverse
correlations to the fibrotic markers.
We initially assessed whether the proteins measured from the sputum samples of
the subjects in the study were linearly correlated to age and markers of lung function. In
Table 4.3, regression coefficients and p values are listed for each protein versus age,
FEV1 % predicted, and FVC % predicted. A positive linear correlation existed between
TGF-β and age, which was statistically significant. This indicates that the older subjects
had higher concentrations of TGF-β in their sputum. TGF-β concentration was also
positively correlated with FEV1 % predicted, with a p value of 0.0011. When age and
FEV1 % predicted were compared, the correlation was negative; therefore some other
factor must be influencing TGF-β. The correlation between MMP-9 and FEV1 %
predicted was also statistically significant, and in this case the correlation was negative.
This is a confirmation of a relationship shown in induced sputum samples, in a study
performed in 20 subjects with CF.[90] . In this study, MMP-9 concentrations were
increased in CF subjects compared to healthy controls, as well as negatively correlated
to FEV1% predicted, as well as neutrophil count. It is, however, interesting that in the
current study MMP-9 is not significantly correlated to age (Table 4.3), although FEV1%
predicted and age are correlated in these subjects. Interestingly, fibronectin is the only
protein significantly correlated to FVC % predicted. While FEV1 is the primary lung
function measurement that is collected and monitored for CF disease progression, FVC
% predicted is also monitored, as this marker begins to decline in late disease[162].
Therefore, the fact that fibronectin is correlated to age and FVC, but not FEV1, is
interesting. This could indicate that fibronectin is also a marker of late disease decline.
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Table 4.3. Proteins measured from subjects sputa compared to age and two different
markers of lung function; FEV1 % predicted and FVC % predicted. Data was analyzed
by linear regression. Regression coefficients and p values reported for each
comparison.
Next, the fibrotic markers were compared to each other to see which were
linearly correlated. As expected, TGF-β and MMP-9 were highly correlated, with a p
value of < 0.0001 (Table 4.4). The correlation between them was a positive one, which
was interesting. This is surprising, given that TGF-β and MMP-9 have opposite effects
on ECM, and would not have been expected to both be increased in the same subjects.
Of additional importance was the finding that MMP-9 and MMP-2 were highly correlated,
with a p value of < 0.0001 (Table 4.4). This is to be expected, given data from other
studies, which suggest that MMP-9 and MMP-2 are upregulated in the same disease
processes in human studies.[68, 163] It is not surprising because the two MMPs are
generally produced at similar levels as demonstrated in the previous figures that assess
the effects of AZM, P. aeruginosa, and S. aureus status in the subjects.
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Table 4.4. Fibrotic proteins measured from subjects sputa compared to markers of ECM
turnover. Data was analyzed by linear regression. Regression coefficients and p values
reported for each comparison.
Lastly, fibrotic mediator concentrations were analyzed against inflammatory
cytokines. We were interested to know if the markers of inflammation were linearly
correlated to markers of fibrosis or ECM turnover. This was important to help determine
if inflammation is associated with fibrosis, or if the shift toward fibrosis includes a shift
away from inflammation. IL-8 was weakly correlated to all four makers of fibrosis, with
very high p values (Table 4.5). IL1-β, however, was strongly positively correlated to both
TGF-β and MMP-9, with p values < 0.0001. IL-1β was correlated with MMP-2 as well,
had a correlation, with a p value < 0.05 (Table 4.5). Interestingly, neither cytokine was
significantly correlated with fibronectin (Table 4.5).

Table 4.5. Fibrotic proteins measured from subjects sputa compared to inflammatory
cytokines measured in subjects’ sputa. Data was analyzed by linear regression.
Regression coefficients and p values reported for each comparison.
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Effect of azithromycin
The linear correlations above were analyzed for all the subjects grouped together
without regard to their status of AZM treatment. This analysis is important in light of our
data presented previously showing no significant difference in the mean concentrations
of these protein concentrations between subjects who are and are not receiving AZM. In
the CF population, AZM is dosed on a daily basis, although there is no standard dosage
recommendation.[92] Traditionally, patients with CF are prescribed AZM once they are
positive for P. aeruginosa, although recent studies have given evidence for physicians to
prescribe this drug for colonization.[103] Because subjects with more progressive
disease should have increased levels of fibrosis, AZM may be functioning to ablate
these effects. We report in Figure 4.6 that certain markers were found to be have
different correlations in subjects receiving AZM compared to subjects not receiving AZM.
TGF-β had a more moderate correlation with FEV1 % predicted in subjects on AZM, with
an r = 0.4058, compared to subjects without the treatment, who had an r = 0.7376. In
this case, the statistical significance remained the same (Figure 4.6a, b). However,
subjects who were not receiving AZM had a very strong correlation of IL-1β to FEV1 %
predicted, with an r = 0.8926 and a statistical significance of p = 0.0029. When subjects
treated with AZM were analyzed similarly, the correlation was found to be far weaker, r =
0.1964, and there was no statistical significance (Figure 4.6c, d).
Similarly, subjects not receiving AZM treatment demonstrated a weak correlation
of r = 0.3458 between TGF-β and MMP-9, a relationship that was not statistically
significant. When these markers were analyzed in subjects on AZM, a regression
coefficient of 0.5973 was observed, which is stronger, and the p value dropped below
0.05 (Figure 4.6e, f). While the study is not able to determine causality, it would appear
that AZM therapy is impacting relationships between proteins and lung function, and
between some proteins among themselves.
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Figure 4.6. Proteins correlated by linear regression to lung function or other proteins.
TGF-β concentrations correlated to FEV1 % predicted compared by linear regression in
subjects either not on AZM (a) or on AZM therapy (b). IL-1β concentrations correlated to
FEV1 % predicted compared by linear regression in subjects either not on AZM (c) or on
AZM therapy (d). TGF-β concentrations correlated to MMP-9 concentrations compared
by linear regression in subjects either not on AZM (e) or on AZM therapy (f) Statistical
analysis was performed with linear regression. Regression coefficients and statistical
significance indicated on the graphs.
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Multifactorial Analysis
In order to better determine the relationships between these proteins, we utilized
principal component analysis as a data reduction method. This allows for simultaneous
evaluation of protein expression variability between the subjects. When the data are
analyzed this way, two primary components appeared in the subjects, The first
component, named PC1, was heavily comprised of TGF-β, MMP-9, and MMP-2, and
accounted for 53% of total variance of the protein expression. (Figure 4.7). The second
component, PC2, was primarily determined by fibronectin and IL-1β concentrations, and
comprised and additional 19% of variability between the samples. Interestingly, IL-8
contributed to both groups(Figure 4.7). When the populations are represented
graphically, the subjects who were not receiving AZM had higher expression of PC1,
while subjects who were receiving AZM had higher expression of PC2. These
associations confirm that fact that TGF-β is highly correlated to both MMPs, as well as
confirming a potential pro-fibrotic role for IL-1β, as it is correlated with fibronectin. The
data also highlight the fact that AZM treatment appeared to be creating two different
populations of protein association.
Additionally, each component was analyzed according to AZM treatment status
and P. aeruginosa colonization status. Subjects receiving AZM treatment are less likely
to be expressing PC1 associated proteins that subjects who are not receiving AZM
(figure 4.8). This is not surprising, when remembering that subjects on AZM had lower
mean TGF-β expression. However, subjects receiving AZM were more likely to be
expressing PC2 associated proteins (Figure 4.8). This suggests that the drug may be
shifting protein expression from PC1 associated proteins toward PC2. However,
colonization with P. aeruginosa did not alter the expression of these proteins to statistical
significance (Figure 4.8). This also suggests that AZM treatment is more influential than
P. aeruginosa colonization.
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Figure 4.7. Principal component analysis of protein expression. a) component matrix
for proteins assessed. Components 1 and 2 accounted for 72% of total variance in
protein expression. b) Component expression in AZM treated subjects (green) and nontreated subjects (red).

Figure 4.8. PC1 and PC2 expression. Expression of each component was compared to
AZM treatment status and P. aeruginosa colonization status. Data are expressed as
mean + 1 SE, and were analyzed with a Mann-Whitney Rank test. * indicates p < 0.05.
Arginase activity
The last goal for the human study was to determine if arginase, the effector
molecule of alternative macrophage phenotype, would be correlated with other markers
of fibrosis or cytokines in subjects with CF. This data is presented in Table 4.6.
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Arginase concentration, assayed by arginase activity normalized to total protein, was
measured in the subjects’ sputa, and analyzed by linear regression with regard to the
markers of fibrosis, as well as cytokines IL-8 and IL-1β. There were no significant
correlations between arginase and any of the proteins measured, nor were these values
changed when the data was analyzed with regard to AZM treatment status.

Table 4.6. Proteins measured from subjects sputa compared to arginase activity. Data
was analyzed by linear regression. Regression coefficients and p values reported for
each comparison.
We also analyzed arginase concentrations with regard to subjects’ AZM
treatment status, colonization with P. aeruginosa, and infection with S. aureus. When
arginase activity levels were compared between subjects who were and were not
receiving AZM therapy, the difference between the two groups were not statistically
significant, Figure 4.7a (p = 0.11). However, there is a trend toward higher arginase
activity in the AZM therapy group, and more subject samples may make this difference
more significant. When arginase concentrations were compared between subjects who
were colonized with P. aeruginosa and those who are not, there was a statistically
significant increase in any concentration in subjects colonized with P. aeruginosa (p =
0.0009, Figure 4.7b). Interestingly, when the comparison was made for subjects with
positive S. aureus cultures vs. subjects with negative S. aureus cultures, there was no
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statistical difference, although there was a trend in the positive group toward higher
arginase activity (Figure 4.7c). Because many of the subjects who were positive for P.
aeruginosa were also positive for S. aureus, we compared arginase concentration
between subjects positive for both organisms, subjects who were positive for only one,
and subjects who were negative for both (Figure 4.7d). In this analysis, the double
positive group had strikingly higher arginase activity levels, statistically significantly
higher than subjects with P. aeruginosa only (p value < 0.01), S. aureus only (p value <
0.0001), and patients colonized with neither pathogen (p value < 0.01). While the
sample sizes of these groups are small, this data is highly suggestive that the
combination of the two pathogens may shift the environment in the lung so that it is
conducive to alternative macrophage polarization. It is also interesting to note that the
other proteins examined in this chapter where analyzed with regard to double infection,
and none of them were found to be affected in this manner.
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Figure 4.9. Arginase production in CF subjects’ sputa. Arginase activity was measured
as described in Methods. Subjects were analyzed with regard to AZM therapy (a),
colonization status of P. aeruginosa (PA) (b), and S. aureus (c). In (d) subjects were
split into PA+Staph+, PA+Staph-, PA-Staph+ and PA-Staph- groups. Data a-c were
analyzed by student’s t-test and considered significant at p < 0.05. Data in graph d was
analyzed via ANOVA with Bonferroni’s post-test for all data. Significance is reported on
graphs, or as p < 0.01 (**) or < 0.0001 (****).
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D. Conclusions
The human study allowed us to draw some interesting conclusions about the use
of AZM in the CF population. While this study did not prove the proposed hypothesis to
be correct, as subjects receiving AZM did not have higher levels of fibrotic protein
concentrations overall, our data indicated that AZM may have a protective role. First,
there were no overall increases in fibrotic mediators associated with AZM therapy as
predicted by our in vitro data; in fact TGF-β was decreased in subjects on AZM.
Because there was also no difference in fibronectin concentrations between the two
groups, this data indicated that AZM may not contribute to increases in fibrosis
development. This data was not surprising in combination with the gene data collected
on the same subjects; fibronectin gene expression also was not increased in subjects
treated with AZM. Additionally, the lack of difference in the two different MMPs
measured shows no effect on ECM turnover when stratifying by AZM treatment. While
presence of P. aeruginosa infection also resulted in lower TGF-β concentrations, further
analysis suggested that this was more reliant on the fact that those patients infected with
P. aeruginosa were being treated with AZM concurrently, confirmed by the PCA data. In
the multifactorial analysis, AZM appeared to be an influential factor in altering protein
expression, while P. aeruginosa colonization status did not significantly alter any
proteins.
Because the subjects recruited were in a non-exacerbated state, inflammatory
cytokines were expected to be of less importance. However, IL-1β exhibited some
interesting differences in these subjects. While apparently not affected by AZM
treatment, there were decreased concentrations of this cytokine in subjects positive for
S. aureus infection compared to subjects who had negative cultures for this pathogen.
This is particularly interesting, given evidence that suggests S. aureus can activate the
inflammasome and induce secretion of IL-1β in monocytes and macrophages.[164, 165]
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Furthermore, both TGF- β and IL-1β concentrations were highly correlated to FEV1 %
predicted in subjects not being treated with AZM, but had markedly reduced correlations
to FEV1 % predicted in subjects on AZM therapy. The alteration in these relationships
suggests that AZM treatment may be affecting the interactions of these molecules in the
mechanism of fibrosis development. Because of IL-1β’s dual role in inflammation and
fibrosis,[160] these correlations become significant.
While this human study was similar to the previous human study performed by
our lab, in that we were unable to significantly associate increased arginase levels with
AZM therapy,[114] similar results were obtained in the association between P.
aeruginosa infection status and increased arginase activity. This subject group showed
a striking trend toward increased arginase concentrations in subjects who were receiving
AZM compared to those subjects who were not. Here, however, we show that subjects
co-cultured with both P. aeruginosa and S. aureus have increased arginase activity,
suggestive of the importance of an alternative macrophage phenotype in these subjects.
This piece of data is quite important in light of the rising incidence of S. aureus infection
in both the CF and the general population. Patients with CF are becoming more and
more likely to be infected with both pathogens. The combination of AZM treatment and
the alternative macrophage phenotype may be compensating to limit damage as lung
function gets work. In vitro data from our lab has demonstrated that AZM does not have
an effect on macrophage phenotype unless the cells are stimulated with LPS.[112] This
may be why there is less arginase activity in subjects with neither pathogen.
Samples from subjects in the current study had been previously analyzed for
gene markers indicative of macrophage phenotype. The inflammatory gene NOS2,
which encodes for iNOS, was decreased in subjects treated with AZM, corroborating
evidence that AZM and the alternative phenotype may be preventing damage, although
arg1, the gene that encodes for arginase, was unaffected. Inflammatory cytokine genes
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IL-1a and TNFα were positively correlated with FVC% predicted, as was the antiinflammatory cytokine IL-10. Furthermore, principal component analysis was used to
identify groups of patients with CAM and AAM-associated genes. Interestingly, MMP-9
was grouped with CAM-associated genes, while TGF-β was grouped with AAMassociated genes. Given that the proteins are so tightly correlated to each other in the
same patients, their gene groupings are interesting. This may suggest that TGF-β and
MMP-9 are upregulated together in order to prevent a universal shift toward either
fibrosis or damage; neither fibrotic accumulation nor tissue damage is greater.
There are two possible scenarios for the function of AAMs in subjects with CF. In
the first scenario, AAMs are upregulated compared to CAMs, which results in increased
accumulation of fibrosis and lung structure change. In the second scenario, the
increase in AAMs compared to CAMs causes decreased inflammation, which prevents
the need to upregulate fibrosis, and therefore prevents further change in lung structure.
The data collected in the human study, when combined with the data from chapters 2
and 3, suggest that the second scenario Is present in subjects with CF who are treated
with AZM.

Limitations
There were several limitations to this study. First, since the study focused on
subjects with stable disease, most of the CF patients recruited were pediatric, and all the
subjects included in the protein analysis were under 25 years of age. While it is certainly
possible for a patient with CF to have advanced disease at this age, we could be
excluding a subset of the CF population that might be responding to AZM differently due
to their age or disease process. Furthermore, the younger patients, regardless of lung
function, were likely to have experienced fewer exacerbations and fewer types of
infection, which also may be influencing the response of the immune system. Further,
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because we were unable to control how long the subjects had been receiving AZM,
there may be variation in the mediators measured, and may or may not reflect long-term
treatment status.
Importantly, because subjects were recruited from the same clinic, they were all
subject to the same prescribing practices. In this instance, that meant that these
subjects are likely to be on AZM before they are infected with P. aeruginosa, and all of
the subjects that were positive for P. aeruginosa were on AZM therapy. While this is
becoming a national trend, it becomes a complication factor when distinguishing an
effect of the drug vs. and effect of the pathogen. In addition, the effect of AZM seen in
the PCA data may be confounded by disease severity. In the future, we may be able to
separate the subjects into groups based on disease severity, to determine if this has any
effect.
Lastly, because we collected sputum samples, there was some variability
inherent in the study. This was due to variation in the amount of sample collected from
each subject and the processing required. In addition, while subjects receiving oral
glucocorticoids were excluded from the study, the subjects included were still on a range
of medications, including inhaled glucocorticoids, which may confound results.

Copyright © Susan Elizabeth Birket
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Chapter 5: Discussion
A. Overview of Results
The goal of this project was to determine the role of the AZM-polarized
macrophage in the process of ECM protein accumulation through the increased
production of TGF-β and MMP-9. This was pursued by combining in vitro, in vivo, and
human studies to determine the impact of AZM on remodeling and fibrosis mediators in
response to P. aeruginosa. We investigated the impact of the AZM-polarized
macrophage on fibroblasts using in vitro experiments, as well as the role of the AZMpolarized cell in the immune response to P. aeruginosa pulmonary infection. Extending
our studies to human subjects with CF, our work contributes to a more global
understanding of the immunomodulatory impact that AZM therapy can impart during the
progression of CF pathology.

B: Significance
The fibrotic effects of AZM-polarized macrophages
One important function of the macrophage is to secrete chemokines and
cytokines that alter other cell types. Therefore, one goal of the project was to determine
how the AZM-polarized macrophage would affect other cell types, particularly
concerning fibrotic mediator production. The in vitro work helped to identify some of the
interactions between two types of cells involved in the upregulation of fibrotic mediator
production. The single cell line controls run along with the co-culture experiments
showed that the combination of the two cell types together was necessary for the
increases in TGF-β, MMP-9, and fibronectin production.
The response of the macrophage to the drug AZM has, in part, been
elucidated.[112] Our first goal was to continue this work by examining the production of
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molecules from the macrophages polarized with AZM, as well as to investigate the
effects of this macrophage on fibrotic mediators produced from fibroblasts. In the lung,
macrophages move to the site of injury, as part of the initial immune response, where
they must interact with the resident cells. In this initial investigation, we found that the
interaction with fibroblasts allowed the AZM-polarized macrophage to increase
production the pro-fibrotic molecules arginase, TGF-β, and fibronectin. From the studies
outlined in Chapter 1, the associated increases of these three molecules were not
unexpected. However, the shift toward fibrosis was not universal; AZM treatment did not
increase collagen I or III, and it also increased the production of MMP-9, a protease.
This shows that the AZM-polarized macrophage does not share all the characteristics of
the typical IL-4/IL-13 stimulated AAM.[27]
The increase in MMP-9 concentrations caused by the addition of AZM was an
unexpected result. Of importance, increased MMP-9 concentrations were not
dependent on either TGF-β (as shown in the TGF-β neutralization experiments) or
arginase (as shown in the arginase inhibitor experiments), while increased fibronectin
production was dependent on both TGF-β and arginase. Because MMP-9 was not
dependent on either, it was hypothesized that TGF-β may in fact be activated by the
protease as an important mechanism in this setting as AZM drives macrophage
polarization; the ability of MMP-9 to activate TGF-β has been shown in a model of tumor
invasion.[127] However, this was not shown to be the case when MMP-9 itself was
inhibited. A possible role for MMP-9 in fibronectin upregulation, however, was observed.
MMP-9 and fibronectin have been linked in previous studies; fibronectin production can
induce MMP-9 upregulation. When fibronectin is directly added to human monocytes in
the presence or absence of TNF, MMP-9 protein is secreted; in addition, greater
amounts of MMP-9 are produced when the fibronectin is added as specific
fragments.[77] This indicates that already degraded fibronectin may initiate a positive121

feedback loop to accelerate its own degradation. In a wound healing assay in vitro, cells
were treated with fibronectin, causing an increase of MMP-9 mRNA and protein
activation, compared to cells not treated with fibronectin. Cell migration was observed in
these wells.[166] This suggests that MMP-9 is degrading fibronectin in order to facilitate
migration to sites of wound healing. Addition of a fibronectin neutralizing antibody
prevented the increase in MMP-9 production, suggesting that fibronectin itself is the
molecule that triggered the increased production of the protease.[167] However, the
ability of MMP-9 to affect fibronectin is a functional role that has not previously been
published.
The in vitro experiments also confirmed a possible mechanism for AZM’s ability
to polarize macrophages to an alternative-like phenotype. Previous results from our lab
suggest that AZM reduces arginase production when the molecule IKK-β is inhibited.
Here we extend these results to show that production of downstream effector molecules
are also reduced when this inhibitor is added. AZM-polarized macrophages do not
appear to have the same effect on fibroblasts when IKK-β cannot signal properly.
Multiple studies have now shown that AZM has the ability to decrease NF-κB activity. In
epithelial cells with a mutated CFTR, AZM treatment reduces DNA binding by NF-κB in
vitro.[101] When epithelial cells are treated with AZM, there is less nuclear translocation
of NF-κB, resulting in less upregulation of IL-8 in response to LPS.[168] The effect of
AZM on NF-κB has been shown in human cells as well; in human tracheal aspirates
taken from premature infants, AZM suppressed NF-κB activation and subsequently IL-8
secretion when the cells were cultured ex vivo.[169] In dendritic cells, inhibition of NFκB activation by AZM also inhibits maturation and function of these cells.[170]
Previous data from our lab has isolated IKK-β as an important molecule in this
pathway; AZM treatment dramatically increases expression of this protein. Work done
by Fong, et al, has demonstrated that IKK-β can inhibit inflammatory functions in
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macrophages by preventing Stat-1 activation.[113] Our previous data has shown both
an increase in IKK-β expression and a decrease in cytokines downstream of Stat-1
signaling.[112] Possible IKK-β/Stat-1 cross-talk may help explain how AZM is able to
downregulate the inflammatory cytokines and effector proteins, such as iNOS, and allow
increase of alternatively activated-associated effector proteins instead. Current work is
under way to investigate the interaction between these two signaling molecules in our
AZM treatment model.

The AZM-polarized macrophage in the lung
When the AZM treatment during infection with P. aeruginosa was investigated in
vivo, there was added complexity to the results obtained upon examining the interactions
of the fibrotic mediators and cellular responses. This was not unexpected, given that
there are many more cell types involved in the pulmonary immune response, and that
the resolution of the infection occurs over weeks rather than days. The complexities
included movement of the important mediators and cells from the lung interstitium into
the alveolar space, as measured by bronchoalveolar lavage. Treatment with AZM has
been shown to decrease neutrophilic influx in a model of endobronchial infection with P.
aeruginosa, although this study did not examine the effect on macrophages in response
to either infection or AZM. [171] The response of macrophages, however, is important,
because Cftr-/- mice have been shown to respond to P. aeruginosa with an increase in
macrophage influx when treated with AZM.[172] Furthermore, this shift from neutrophilic
to monocytic response is also observed when erythromycin is used for pre-treatment
during P. aeruginosa infection.[173] Therefore, it was important to determine the
function and phenotype of these macrophages. The most striking result was that the
increased numbers of macrophages in the BALF in the C57Bl/6 mice occurred at the
same timepoint as the increased concentrations of MMP-9 and fibronectin in BALF in the
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mice treated with AZM. Given that MMP-9 is so often strongly associated with
neutrophil count [85, 142, 148, 174], it is an important distinction that MMP-9 is
increased when neutrophils are decreased in this model. Lastly, these changes
temporally followed a shift in the lung of expression from the CAM marker iNOS toward
the AAM marker arginase in the same mice, as was also observed in vitro.
The mice that produce more iNOS had more evidence of pulmonary damage as
a result of P. aeruginosa infection after resolution. The IL-4rα-/- mice that did not receive
AZM continued to express iNOS until day 14 post-infection, and had significantly higher
amounts of peribronchiolitis and alveolitis at day 14 compared to the same mice treated
with AZM. This group did not have higher arginase concentrations in the lung but did
have decreased iNOS at day 14, indicating that AZM’s effect on iNOS may be the
important factor in decreasing damage. Similarly, the C57Bl/6 mice of both treatments
have less iNOS expression at day 7 compared to day 3, and the damage in these mice
was less than in the IL-4r-/- mice. Increase in iNOS expression, and a general switch to
a more CAM-like phenotype in the absence of IL-4 and IL-13 signaling, has been
previously shown in the IL-4rα-/- mice.[175, 176] These studies utilized parasitic infection
models to drive macrophage polarization toward AAMs.

The adoptive transfer

experiment confirmed that the alternative macrophage can be protective - the shift away
from iNOS expression may be one of the protective effects of this phenotype. The shift
from iNOS to arginase has been shown in multiple models as macrophages become
alternatively activated, in response to cytokines, tumors, or infection.[26, 176, 177] The
identification of decreasing iNOS as the protective event is confirmed by a study of iNOS
knockout mice that were resistant to injury and fibrosis secondary to bleomycin
administration.[178] Likely the contribution to inflammation made by iNOS is initiating
the repair processes causing the disease. When iNOS is decreased, less damage
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occurs, requiring fewer repair processes. This illustrates one way by which AZM may
decrease damage caused by infection and inflammation.
The effect of AZM in the lungs of mice infected with P. aeruginosa was examined
as well. By histological analysis, lungs of mice treated with AZM before and during
infection showed increases of arginase expression accompanied by a decrease of iNOS
expression; suggesting a shift of the macrophages toward an AAM phenotype. The
increases in arginase in the lung at day 3 were followed by an increased concentration
of both MMP-9 and fibronectin in the BALF of the AZM-treated mice at day 7. This is
significant, because the increases in arginase preceded the increases of MMP-9 and
fibronectin observed in vitro. Interestingly, the opposite effect was seen by histology;
MMP-9 and fibronectin were reduced in the lung tissue in AZM-treated mice. This may
be because the histological analysis stains for all the cell types in the lung, while the in
vitro studies were limited to macrophages and fibroblasts. It has been shown by others
that AZM can decrease MMP-9 production from epithelial cells. [143] Fibronectin is also
made from many cell types, including epithelial cells, [179], and its production may be
affected differently by AZM in these cells. In contrast, the majority of cells in the BALF
tend to be immune cells, which may be why this fraction was affected by AZM in the way
that was predicted by the in vitro experiments.
However, when examining the histology of the lungs to evaluate damage caused
by the infection, there are some observations to be made beyond the pathologies that
were compared. The mice that were treated with AZM had histological changes at day
14 that were not inflammatory in nature. This may indicate a type of pathology that is
more common in another disease state. For instance, chord length (the measurement
between alveoli), was not measured in our studies. This is a pathology that appears in
certain types of COPD, but is not indicative of inflammation, infection, or fibrosis,[180]
and yet may be altered by the treatment. Because we were unable to examine
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physiological endpoints in the mice, and because the experiments lasted only 14 days,
we were unable to determine whether the AZM-treated mice experienced any other
consequences of treatment, such as change in elasticity or compliance of the lung.
When the lungs of each group of mice were examined for damage and markers
of pathology, there were some interesting differences. Overall, the lungs of the mice
treated with AZM appeared to have less damaged, but the architecture was altered
compared to baseline. There was overall increased alveolar size in the AZM treated
mice, especially at later timepoints. However, the drug did reduce bronchitis and
alveolitis at early timepoints – yet alveolitis and interstitial pneumonitis were increased
by the AZM at later timepoints. The AZM-treatment group also showed increased
collagen accumulation at the latest timepoint compared to the vehicle group. However,
the collagen was accumulated to the bronchi, and there was no difference in bronchitis
at day 14 between the two groups. Therefore, it is unclear if the collagen accumulation
is physiologically significant.
This increase in collagen observed in the mouse model of infection was not
present during the in vitro experiments. This may be due to the fact that the increase
happens late – 14 days post-infection. This type of chronic infection is difficult to
replicate in cell culture, as cell viability becomes an issue. This may account for the
difference observed in the co-culture – 48 hours may still be too early for any increase in
collagen to appear.
Evaluation of pathologic processes in the IL-4rα-/- mice were quite different
between the treatment groups. Peribronchiolitis and alveolitis were less severe in the
AZM treatment group at days 7 and 14 compared to the vehicle groups, and bronchitis
was less severe in the AZM group at day 7. Based on this difference, IL-4rα-/- mice were
given either T cells or monocytes and T cells by adoptive transfer. In this experiment,
the mice that received both types of cells had less alveolitis and interstitial pneumonitis,
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although the differences were not statistically significant. The damage in the mice that
received T cells alone mimicked the damage seen in IL-4rα-/- infected with P.
aeruginosa, but not treated with AZM. Those mice that receiving monocytes and T cells
more resembled the IL-4rα-/- mice that were infected but also received AZM; however the
addition of monocytes did not reduce the damage to the degree that the drug did. This
could indicate that the IL-4rα-/- which receive normal T cells and monocytes may be able
to polarize to an alternative phenotype in response to infection. However, the presence
of AAMs does not reduce inflammation as much as the administration of AZM.

Fibrotic mediators in human subjects
For our human study, we were unable to enroll subjects who were infected with
P. aeruginosa and simultaneously not treated with AZM. This is due to the current
practice of having all or most patients with CF who are infected with P. aeruginosa on
AZM. For this reason, we did not have the comparison group that we had in the cell
culture and mouse studies. This heightens the importance of our complimentary
evaluation in our in vitro and mouse models.
The study performed in human subjects with CF followed up on examination of
the fibrotic mediators studied in the other models. We expected subjects treated with
AZM to have increased markers of fibrosis compared with subjects who were not on
AZM therapy. However, subjects receiving AZM had decreased concentrations of TGFβ in their sputum. This change was consistent in subjects with positive P. aeruginosa
cultures compared to subjects who were negative for this pathogen. Because the
subjects who were colonized with P. aeruginosa were all on AZM, it was difficult to
elucidate which was the underlying factor causing the decreased TGF-β concentrations.
There are no published reports of changes in sputum TGF-β concentrations associated
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with the presence of P. aeruginosa, although there is some evidence that plasma TGF-β
levels are increased in the presence of the pathogen.[72] This was shown in a study of
40 children, comparing those with and without P. aeruginosa positive cultures. In this
same study, BAL concentrations of TGF-β were not affected by presence of P.
aeruginosa. However, the authors argue that plasma concentrations of TGF-β are a
reliable indicator of lung environment, as they correlated with BAL concentrations.
Interestingly, more of the subjects in the study were infected with S. aureus than
P. aeruginosa, yet the presence of this pathogen did not appear to affect the presence of
any of the fibrotic mediators. The only protein that was different between subjects based
on their S. aureus infection status was IL-1β; its concentrations were lower in subjects
infected. Simultaneously, IL-β concentrations were not different when analyzed in terms
of AZM treatment or P. aeruginosa infection status. Previously, we found that IL-1β
concentrations are increased in subjects who are positive for P. aeruginosa compared to
subjects who are not. [114] Subjects from these two studies had remarkably similar
demographics, yet the current study excluding patients who were on systemic
glucocorticoids, while the previous study included them. Also, the subjects in the
previous study were not analyzed by presence or absence of S. aureus. These issues
may be the source of variation between the two.
The proteins in the sputa that correlated to each other and to degree of lung
function depict interesting characteristics associating macrophage function and fibrosis
in these subjects. TGF-β was positively correlated to both lung function and MMP-9.
IL-1β was positively correlated with TGF-β, MMP-9, and lung function. This suggests
that these molecules may interact during lung function decline. Furthermore, many of
the correlations were different when the data was analyzed separately by AZM treatment
group. TGF-β and IL-1β have weaker correlations with FEV1 in subjects receiving AZM
compared to subjects who are not. This data indicates that treatment with the drug may
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be changing some of the interactions of the fibrotic and inflammatory mediators we are
examining. Furthermore, that TNF, IL-10, IL-6, and IL-12 were below level of detection
are significant findings. There is evidence that these inflammatory cytokines are
typically elevated chronically in CF,[181] and it was expected that we would have
detectable levels of these cytokines in our subject population. Although the FEV1
measurements would suggest otherwise, the subjects in our study may have been on
average young enough to have mild to moderate disease. Additionally, the above study
did not specify whether the subjects were being treated with AZM. It may be that the
high percentage of AZM treatment in our subjects may be the reason for the decreased
inflammatory cytokines.
Lastly, the AAM effector protein arginase was measured in these subjects. As in
our previous work, arginase concentrations were not different in subjects when analyzed
for their AZM treatment status, although there was a trend toward higher arginase in
those who were treated with AZM. Arginase was, however, increased in subjects
positive for P. aeruginosa, compared to subjects who were negative for this pathogen.
This corroborates conclusions of our previous study.[114] However, in the current study,
subjects were analyzed for double colonization with P. aeruginosa and S. aureus versus
single colonization with either pathogen. Traditionally, patients with CF tend to culture S.
aureus less frequently as they become positive for P. aeruginosa.[5, 182] However, as
S. aureus becomes more prevalent, this appears to be changing,[9] making those
subjects that are culture-positive for both pathogens an important sub-population. It is
important to know how the immune response changes in those patients, and how this
affects their lung function. Those subjects who were positive for both pathogens had
significantly higher arginase activity compared with subjects who were colonized with a
single bacterium. There was no difference between subjects who were singly colonized
and subjects who were negative for both. While we were unable to measure any other
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marker of AAM in these subjects, the increased arginase activity may indicate a shift
toward the alternative phenotype in these subjects. This may not be the case for the
subjects who are not colonized with either bacteria because cells must be stimulated
with a bacterial trigger, like LPS, in order for AZM to have an effect.[112] Additionally,
AZM treatment in subjects with double colonization may be causing and IKK-βdependent reduction in Stat-1 signaling, which would further reduce inflammatory
macrophage products.
Important observations were also made regarding the subjects who were
colonized with S. aureus. While this infection is quite common in both the young CF
population and the general population, there is a current shift from methicillin-senstive
Staphylcoccus aureus (MSSA) to methicillin-resistant Staphylcoccus aureus (MRSA) in
both populations. [5] The current study collected information about which strain the
subjects were infected with, but did not analyze them by resistance profile due to small
sample sizes. Therefore, MRSA status may be a confounder to our results.
Furthermore, as mentioned in Chapter 1, S. aureus is becoming an organism that can
cause chronic colonization in patients with CF. [8] The subjects in this study were not
identified as having transient or chronic S. aureus infections. This may be another
confounder.
It is also important to note that in the in vitro and in vivo studies conducted
previously by our lab, it is evident that AZM does not completely inhibit inflammatory
cytokine production, it merely reduces it. [112, 138] While the in vitro evidence showed
general upregulation of fibrotic mediators from macrophages and fibroblasts by AZM,
those trends were ameliorated in the murine and human studies. These studies also
showed decreases in inflammatory products, such as iNOS, with administration of AZM.
Therefore, the anti-inflammatory properties of the drug may outweigh the pro-fibrotic
ones. In addition, both the in vitro and in vivo studies demonstrated an increase in
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MMP-9 production in AZM treated cells. The decreased inflammation, coupled with the
increased MMP-9, may be why the subjects on AZM in our study do not have any
statistically significant upregulation of fibrotic mediators in their sputa, and may be
grounds for why AZM is effective at decreasing morbidity in patients with CF.
Importantly, the subjects who participated were receiving multiple medications in
addition to AZM. In order to reduce as much variability as possible, the study excluded
known modulators of the immune system, such as systemic glucocorticoids, but all
patients with CF are receiving multiple medications on a daily basis. These range from
mucolytics to digestive aids.[92] While we did not find any statistical significance in the
data, one drug of interest was inhaled tobramycin. This is given to patients who are
positive for P. aeruginosa cultures, but on a 28-day on, 28-day off cycle.[87] Therefore,
the 28 days in which the patients are on both AZM and inhaled tobramycin may produce
different immune responses than the 28 days in which the same patients are on only
AZM. While tobramycin does not have immunomodulatory properties, the drug may be
altering organism burden and indirectly affecting the immune response. This is a facet
of treatment that we were unable to examine in our study, but may warrant further
investigation.
Furthermore, the subjects were specifically chosen for their status of stable
disease, as AZM is given to CF patients as part of maintenance treatment intended to
decrease frequency of exacerbation. However, because AZM affects the inflammatory
cytokine response, it is still unknown how the relationships between the fibrotic
mediators and those cytokines might change during an acute exacerbation. This is a
difference from the in vitro and in vivo models, which studied the initial and resolution
phases of the response to the bacterium. These types of comparisons are not possible
in our human studies as designed. Future work will investigate these issues.
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Future Directions
The conclusions made in the experiments outlined here provide the foundation
for further investigation into mechanism of fibrosis development and turnover. While we
examined the interactions of several mediators in depth, there are some interactions that
warrant future study.
MMP-9 was identified during the in vitro experiments as having direct impact
upon the development of fibrosis, and was increased by the addition of AZM in the
absence of any other stimuli. However, the inflammatory response early after infection
in MMP-9-/- mice was not examined, nor was macrophage phenotype. There may be
differences in macrophage and neutrophil influx in mice that lack MMP-9, and therefore
differences in upregulation of iNOS and arginase. More in vivo experiments to evaluate
these parameters and determine the exact mechanism of MMP-9 in the response of P.
aeruginosa could be important. Most of the in vivo work done with MMP-/- mice have
studied diseases of pulmonary structure, such as bronchopulmonary dysplasia, or
ventilator associated lung injury.[141, 142] These studies demonstrate that lack of
MMP-9 protects against ventilator induced lung injury, but also induces alveolar
hyperplasia and promotes eosinophilic inflammation, suggesting a more complex role in
inflammation for the molecule.[140] The preliminary work outlined in Chapter 3 indicates
that the long-term effects of MMP-9 deficiency could also increase fibrosis. The data
collected was not sufficient to determine the full nature of MMP-9’s role in the response
to bacterial infection, however. This could be important, especially since the control
mice exhibited a neutrophilic response to P. aeruginosa infection.[114] Neutrophils are
pre-loaded with MMP-9 filled granules – without MMP-9, response of these cells to P.
aeruginosa may not be the same, nor may the resultant damage and repair.[79]
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Investigation early in the course of infection may help elucidate the importance of MMP9 in neutrophilic influx, and therefore, subsequent pulmonary damage.
IL-1β was shown to be affected by AZM treatment in the human subjects, but we
did not investigate this molecule in the mouse models of infection. It is known that IL-1β
can have effects on both inflammatory and fibrotic processes by increasing TNF and IL6, as well as TGF-β and fibrotic mediators.[160] IL-1β can affect macrophages directly –
inducing production of IL-8 and TNF, as well as later increases in fibrotic proteins such
as TGF-β in diseases like idiopathic pulmonary fibrosis.[15, 119, 183] Given this dual
role, it is likely that IL-1β production is increased in response to P. aeruginosa infection,
and may be subsequently decreased by treatment with AZM. Because our human study
did not include subjects who were positive for P. aeruginosa but not receiving AZM, we
were not able to assess this affect on IL-1β accurately. In future experiments, our group
will investigate this in our murine infection model.
Lastly, a major limitation of the clinical study was the limited availability of
subjects who were not being treated with AZM. The imbalance of subjects in each
treatment group made the statistics difficult to assess. Next, we plan to do a crossover
study, in which subjects are taken off of AZM, a suitable washout period is observed,
and the same markers measured during and AZM-negative course. This would not only
allow us to generate more AZM-negative samples, but also to have more rigid, matched
controls. We would observe the same subject both on and off the drug; therefore the
changes that occur in the production of proteins examined would be more confidently
attributed to AZM.
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C. Conclusions
This research provides insights into the mechanisms by which AZM can influence
fibrosis development in the setting of P. aeruginosa infection. We have identified one
potential mechanism by which AZM is shifting macrophages toward an AAM phenotype,
as well as the resultant functional characteristics through which these macrophages are
then increasing fibrogenesis. This appears to be occurring through the increased
production of IKK-β, which then leads to increased production of arginase, increased
activation of TGF-β, and increased production of fibronectin. Additionally, AZMpolarized macrophages are different from typical IL-4/13 stimulated AAM, in that MMP-9
protein production is increased as well.
In vivo, we confirmed the impact exerted by AZM on some of these pathways,
but also showed that the presence of the alternative phenotype may be globally
protective. When faced with an acute infection, the presence of this AZM-polarized
macrophage may blunt the damage associated with neutrophil-driven inflammation and
prevent the need for later upregulation in airway repair. This is supported by the
decrease in iNOS production in the AZM-treated mice. Therefore, the AZM-polarized
macrophage may still be producing some fibrotic proteins, but the need to incorporate
them into fibrotic tissues may be lessened. Interestingly, the two fibrotic proteins
studied, fibronectin and collagen, were impacted oppositely when mice were treated with
AZM; fibronectin concentration in the lung was decreased, while collagen concentration
around the airways was increased. Because the increased collagen was accompanied
by decreases in lung damage, it is difficult to ascertain what the physiologic
consequences of the increased collagen might be.
The human study provided us with insights into how the fibrotic markers and
inflammatory cytokines interact with each other. The proteins studied reflect not a global
shift toward either fibrosis or inflammation, but rather a possible return to homeostasis
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when the drug AZM is present. Additionally, treatment with AZM altered relationships
between fibrotic mediators and inflammatory cytokines, as well as between specific
proteins and lung function. Interestingly, arginase production was only increased in
subjects who were positive for both P. aeruginosa and S. aureus, indicating that double
colonization may drive the lung away from a highly inflammatory state as a protective
mechanism. While subjects on AZM did not have significantly higher arginase
production compared to subjects not on AZM, there was a trend that might grow stonger
with more subjects.
Altogether, the three approaches used in this study gave us complementary
insights into the mechanism of AZM’s impact on fibrosis development, allowing us to
reach a better understanding of how AZM-polarized macrophages affect fibrosis
development during P. aeruginosa infection.
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